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TPMT, thiopurine methyltransferase.BACKGROUND & AIMS: We aim to provide guidance for
medical treatment of luminal Crohn’s disease in children.
METHODS: We performed a systematic search of publication
databases to identify studies of medical management of pedi-
atric Crohn’s disease. Quality of evidence and strength of rec-
ommendations were rated according to the GRADE (Grading of
Recommendation Assessment, Development, and Evaluation)
approach. We developed statements through an iterative online
platform and then finalized and voted on them. RESULTS: The
consensus includes 25 statements focused on medical treat-
ment options. Consensus was not reached, and no recommen-
dations were made, for 14 additional statements, largely due to
lack of evidence. The group suggested corticosteroid therapies
(including budesonide for mild to moderate disease). The group
suggested exclusive enteral nutrition for induction therapy and
biologic tumor necrosis factor antagonists for induction and
maintenance therapy at diagnosis or at early stages of severe
disease, and for patients failed by steroid and immunosup-
pressant induction therapies. The group recommended against
the use of oral 5-aminosalicylate for induction or maintenance
therapy in patients with moderate disease, and recommended
against thiopurines for induction therapy, corticosteroids for
maintenance therapy, and cannabis in any role. The group was
unable to clearly define the role of concomitant immunosup-
pressants during initiation therapy with a biologic agent,
although thiopurine combinations are not recommended for
male patients. No consensus was reached on the role of ami-
nosalicylates in treatment of patients with mild disease, anti-
biotics or vedolizumab for induction or maintenance therapy,
or methotrexate for induction therapy. Patients in clinical
remission who are receiving immunomodulators should beassessed for mucosal healing within 1 year of treatment initi-
ation. CONCLUSIONS: Evidence-based medical treatment of
Crohn’s disease in children is recommended, with thorough
ongoing assessments to define treatment success.Keywords: GRADE; Inflammatory Bowel Diseases; IBD; TNF.
hile inflammatory bowel disease (IBD) hasWbecome a global disease, the incidence and prev-
alence of both pediatric- and adult-onset IBD in Canada
remain among the highest worldwide.1,2 Canadian data
suggest that the incidence may have stabilized among
adults, but continues to increase in children, reaching 9.68
(95% confidence interval [CI], 9.11–10.25) per 100,000 
children under age 16 years for the period 1999–2010.2 
Although the highest percentage increases in incidence 
were among children aged younger than 5 years at time of 
diagnosis, pediatric-onset IBD still develops most commonly 
in adolescence.2 Crohn’s disease (CD) predominates over 
ulcerative colitis, accounting for 65.6% of pediatric IBD 
based on national administrative data up until 2010,2 and 
occurring in 62% of 1146 children in the Canadian Children 
IBD Network inception cohort study.3
Pediatric CD encompasses a heterogeneous spectrum of 
phenotypic features (as recognized by the Paris modifica-
tion of the Montreal classification4), disease severity, and 
treatment responsiveness. Intestinal healing, rather than 
symptom control alone, has become an important thera-
peutic goal.5 This may be especially important in young 
patients, given the potential for growth impairment as a 
direct effect of persistent chronic inflammation6,7 and their 
long lives ahead, during which disease complications may 
occur. Mucosal healing became a realistic goal for patients 
with the advent of monoclonal antibodies directed against 
tumor necrosis factor (TNF)-a. As alternate pathway bio-
logic agents and new small molecule therapies emerge, it 
behooves clinicians to recommend treatment of pediatric CD 
based on critical evaluation of efficacy and safety. Choice of 
treatment for active pediatric CD must always be made with 
a maintenance strategy in mind.
When the pediatric consensus group met in October 
2017, the most recent consensus guidelines for the treat-
ment of CD in pediatric patients were those from the Eu-
ropean Society of Pediatric Gastroenterology, Hepatology 
and Nutrition and the European Crohn’s and Colitis Orga-
nization published in April 2014, which incorporated data 
published until June 2013.8 The Canadian Association of 
Gastroenterology (CAG) has established infrastructure for 
the development of consensus clinical practice guidelines,9 
but to date has focused on adult patients, including 
consensus guidelines for both luminal and fistulizing CD. 
Given the increasing prevalence of pediatric CD, the chal-
lenges specific to young patients, and the uncertainties 
around treatment choices, the Canadian Children IBD 
Network partnered with CAG to systematically review the 
literature relating to the medical management of luminal CD 
and to develop specific recommendations for pediatric 
patients.Methods
Scope and Purpose
This guideline focuses on the medical management of 
luminal CD in pediatric patients, and does not specifically 
address the diagnostic evaluation of luminal CD, the role of 
surgical management, growth monitoring, social and psycho-
logical interventions, and preventative health measures, such as 
vaccinations. Specific questions pertaining to the medical 
management of luminal CD in pediatric patients were devel-
oped by the steering committee (DM, AG, EIB, JC, JD, and JM) 
and GRADE (Grading of Recommendation Assessment, Devel-
opment, and Evaluation) experts (PM, FT). Recommendationswere developed by all members of the group at a face-to-face
meeting in October 2017.Definitions Used in Framing Questions
Disease activity. The categories of disease activity dis-
cussed in this guideline (mild to moderate and moderate to
severe active CD) were defined in many clinical trials according
to the Crohn’s Disease Activity Index in studies involving adult
patients or the Pediatric Crohn’s Disease Activity Index in
studies involving children. Therefore, in general, descriptions of
activity in this document reflect Crohn’s Disease Activity Index
or Pediatric Crohn’s Disease Activity Index scores, as described
in the evidence.
Outcomes. Clinical remission was consistently chosen as
the primary outcome in the statements because of knowledge
that until recently “clinical remission” (usually defined by a
multi-item measure of disease activity) has been the primary
end point in clinical trials assessing treatment efficacy.
Evidence of efficacy of specific treatments in achieving
mucosal healing is limited, therefore, “complete” or “deep”
remission (clinical remission plus mucosal healing) was not the
chosen primary outcome in this guideline. Mucosal healing,
however, is increasingly replacing “clinical remission” as a
treatment target for adults and children with IBD.5 Such healing
has been associated with sustained clinical remission and a
reduced need for hospitalization and surgery.10–12 Statements
regarding the importance of evaluating mucosal healing in pe-
diatric patients achieving clinical remission were therefore
discussed, despite the limitations of existing data precluding its
choice as a primary outcome.
Clinical response was defined as reduction in symptoms
determined by clinically meaningful changes in a multi-item
measure of disease activity, in the absence of complete reso-
lution of symptoms.Sources and Searches
A systematic search of the literature relevant to the selected
questions from January 2000 to June 2017 was conducted by
the Editorial Office of the Cochrane Upper Gastrointestinal and
Pancreatic Diseases Group at McMaster University using
MEDLINE, EMBASE, Cochrane Central, and Cochrane database
of systematic reviews. Key search terms included pediatric,
Crohn’s, antibiotic, 5-aminosalicylate, corticosteroid, anti-tumour
necrosis factor, thiopurine, methotrexate, vedolizumab, usteki-
numab, and enteral nutrition. The search was limited to human
studies and English publications; additional details of the
search strategies utilized are provided in the Supplementary
Material Appendix 1.
The consensus process was facilitated by the CAG via a web-
based consensus platform (ECD Solutions, Atlanta, GA). Using
this platform, the steering committee reviewed the results of
initial literature searches and identified relevant references
that were then “tagged” (selected and linked) to each state-
ment. Copies of the tagged references were available to all
members of the consensus group. The full consensus group
voted anonymously on their level of agreement with the indi-
vidual statements, using a modified Delphi process.13,14 Par-
ticipants suggested revisions and commented on the
statements, after which, the specific statements were revised
through 2 iterations.
Assessment of the Quality of Evidence
Two non-voting methodologists (PM, FT) used the GRADE 
approach15 to assess the strength of the evidence for each 
statement. The quality of evidence for each consensus state-
ment was classified as high, moderate, low, or very low, as 
described in GRADE15,16 and used in previous CAG consensus 
guidelines.17–21 Randomized controlled trials (RCTs) began as 
high-quality evidence but could be downgraded because of 
heterogeneity or inconsistency of results, imprecision, indirect 
study findings, reporting bias, or if it was determined that a 
high risk of bias existed across studies supporting the state-
ment. Data from observational studies began as low-quality 
evidence, but could be lowered because of the same factors, 
or raised if a very large treatment effect or a dose–response 
relationship was identified, or if all plausible biases would 
change the magnitude of effect toward the opposite 
direction.15,16
Using the GRADE approach, it is rare to have high-quality 
evidence unless it fulfills all domains in terms of risk of bias, 
inconsistency, imprecision, indirectness, and no other bias (eg, 
publication bias). The evidence is always reviewed in relation 
to the PICO (patient population, intervention, comparator, and 
outcome) question. So, the trials may be high methodological 
quality, but if they do not address the PICO question directly in 
terms of populations, interventions, and outcomes, the evidence 
will be downgraded. In addition to an updated review of the 
literature, new meta-analyses were performed for this 
consensus.
Much of the evidence for the efficacy and safety of CD 
treatments was available from RCTs conducted in adult pop-
ulations. In some cases, the quality of evidence was down-
graded for indirectness with respect to the populations when 
no studies were found that evaluated the drug in children, and 
as such both safety and effectiveness data had to be extrapo-
lated from adult studies. Considering the course of disease, 
responses to treatments and dose–response relationships may 
differ between pediatric and adult populations with CD and, as 
such, the evidence was less certain in children than in adults 
when only adult data were available. However, if there were 
studies done in children (even observational in nature) that 
supported the findings in adults, the evidence was not down-
graded for indirectness. In some cases, when confronted by 
very-low-quality evidence in the absence of a compelling 
benefit to risk ratio, the consensus group agreed not to make a 
recommendation for or against a particular strategy.
Approved product labeling from government regulatory 
agencies varies from country to country, and although it was 
not ignored, recommendations were based on evidence from 
the literature and consensus discussion, and may not fully 
reflect the product labeling for a given country.
Consensus Process
The 2-day, face-to-face consensus meeting was held in 
Toronto, Ontario, Canada, in October 2017. The consensus 
group was composed of 15 voting pediatric gastroenterologists, 
from Canada and the United States with expertise in multiple 
areas, including nutrition (SL, WE, HH, AO), growth impairment 
in IBD (TW, AG), microbiome (DM), clinical epidemiology, 
health services research and quality improvement (EB, PJ, AO, 
MS, MDK, WE), and patient-reported measures or patient 
engagement (AO, MDK). Non-voting participants included theco-chairs (AG, DM), GRADE experts (PM, FT), a representative
from the adult CD CAG consensus group (JM), non-voting ob-
servers, and the co-moderators (PM, DS). At the consensus
conference, data and the GRADE evaluations of the evidence
were presented, and each individual statement was discussed
and the wording finalized. Participants voted on their level of
agreement for each statement. If 75% of participants voted 4
(agree) or 5 (strongly agree) on a 1–5 scale (1, 2, and 3 being
disagree strongly, disagree, and uncertain, respectively), then
the statement was accepted. If a statement was accepted, a
second vote on the strength of the recommendation was con-
ducted. A level of agreement of 75% of participants was
needed to classify a statement as “strong” (we recommend); if
this threshold was not met, the statement defaulted to “con-
ditional” (we suggest). The strength of a recommendation
considers the benefit-to-risk balance, patients’ values and
preferences, cost and resource allocation, and the quality of the
evidence. Consequently, a recommendation could be classified
as strong despite low-quality evidence, or conditional despite
high-quality evidence.22 As per the GRADE method, a strong
recommendation is indicative of a more broadly applicable
statement (“most patients should receive the recommended
course of action”), whereas a conditional recommendation
suggests clinicians should “. . . recognize that different choices
will be appropriate for different patients and that they must
help each patient to arrive at a management decision consistent
with her or his values and preferences.”22
During the consensus meeting, voting members were un-
able to reach consensus on 14 statements (No recommendation
A–N) and these statements were rejected. The evidence that
was reviewed for these statements and the discussion has been
summarized in the text, but the consensus group did not make
a recommendation for or against these treatment strategies.
The manuscript was initially drafted by the co-chairs (DM,
AG), and then reviewed and revised by the GRADE experts and
members of the steering committee before being sent to the full
consensus group for review. Upon approval from the group, the
manuscript was made available to all CAG members for
comment during a 2-week period before submission for
publication.
In accordance with CAG policy, written disclosures of any
potential conflicts of interest for the 24 months preceding the
consensus meeting were provided by all participants, and made
available to all group members, and CAG members reviewing
the manuscript.
Role of the Funding Sources
Funding for the consensus meeting was provided by unre-
stricted, arms-length grants to the CAG by AbbVie and Takeda
Canada, and a Planning and Dissemination Grant from the Ca-
nadian Institutes of Health Research. The CAG administered all
aspects of the meeting, and the funding sources had no
involvement in the process at any point, nor were they made
aware of any part of the process from development of search
strings and statements to drafting and approval of these
guidelines.Recommendation Statements
The individual recommendation statements are pro-
vided and include the strength of recommendation and
Statement 1: In patients with moderate Crohn’s
disease, we recommend against the use of 5-
aminosalicylates to induce clinical remission.
GRADE: Strong recommendation, very-low-quality
evidence.
Vote: strongly agree, 67%; agree, 33%.
No consensus A: In patients with mild Crohn’s disease,
the consensus group does not make a recommendation
(for or against) regarding the use of 5-aminosalicylates to
induce clinical remission.
Key evidence. Two systematic reviews and meta-
analyses (SR&MAs),23,24 and a network meta-analysis
(NMA) of studies in adults provide data on the use of 5-
aminosalicylate (5-ASA) in mild to moderate active CD.25
These analyses included studies using various formula-
tions and doses of non-sulfasalazine 5-ASAs (ie, mesalamine
and olsalazine), and generally reported no benefit with
these agents over placebo for induction of remission. In 1
analysis of 4 trials (n ¼ 647), the relative risk (RR) of failure
to induce remission with mesalamine compared with pla-
cebo was 0.91 (95% CI, 0.77–1.06).23 One SR&MA reported
no significant benefits with either low-dose or high-dose 5-
ASA,24 while the NMA showed that high-dose mesalamine
was superior to placebo in inducing remission (odds ratio
[OR], 1.87; 95% credible interval, 1.14–3.15), but low-dose
was not.25 In the induction studies, there was no signifi-
cant difference noted in adverse events between mesal-
amine and placebo (RR, 0.99; 95% CI, 0.84–1.15).23
The data did not assess mild and moderate disease
separately, and no RCTs in pediatric patients were found.
The quality of evidence was downgraded to very low due
to serious risk of bias, serious indirectness with respect to
populations (lack of pediatric data and inability to separate
mild from moderate disease), and very serious imprecision.
Discussion. The SR&MAs generally do not report a
statistically significant efficacy with 5-ASA for induction
therapy in patients with mild to moderate disease activity,
but also do not convincingly demonstrate that 5-ASAs are
without benefits (eg, potential benefits with high-dose
therapy25). The data cannot be separated into mild and
quality of supporting evidence (according to the GRADE 
approach), and the voting result. This is followed by a dis-
cussion of the evidence considered for the specific state-
ment. A summary of the recommendation statements is 
provided in Table 1. See Supplementary Material Appendix 
2 for more detailed quality of evidence summaries.
The majority of RCTs in patients with CD are conducted 
in adults, and therefore much of the evidence has been 
downgraded for indirectness and is of very low quality. As a 
result of the very low quality of evidence, there were 
insufficient data for the consensus group to make recom-
mendations for or against many treatments (14 statements); 
however, the available evidence and ensuing discussion 
relevant to these treatments is presented.
Aminosalicylatesmoderate patients, however, the group strongly recom-
mended against this option in patients with moderate (or
greater) disease activity, because of the potential negative
consequences of delaying the use of other therapies with
more definitively demonstrated efficacy.
Data specifically in patients with mild disease were
lacking, and the consensus group concluded that the evi-
dence was not sufficiently convincing to recommend for or
against 5-ASA for mild CD. The potential negative conse-
quences of delaying use of more effective treatments would
be of less concern than in the case of moderate CD. An
additional concern was the rare cases of pancreatitis and
interstitial nephritis that have been reported with
mesalamine.26
In summary, because 5-ASAs have not demonstrated a
consistent, significant benefit, the consensus group made a
strong recommendation against their use in patients with
moderate CD. However, because ineffectiveness in mild
disease was not demonstrated in the literature, no recom-
mendation was made for or against its use to induce clinical
remission in patients with mild disease.
Statement 2: In patients with moderate Crohn’s
disease limited to the colon, we suggest against the
use of sulfasalazine to induce clinical remission.
GRADE: Conditional recommendation, very-low-quality
evidence.
Vote: strongly agree, 67%; agree, 20%; neutral, 7%;
disagree, 0%; strongly disagree, 7%.
No consensus B: In patients with mild Crohn’s disease
limited to the colon, the consensus group does not
make a recommendation (for or against) regarding the
use sulfasalazine to induce clinical remission.
Key evidence. There was very limited evidence on the
efficacy of sulfasalazine in CD. The 2 SR&MAs,23,24 and the
NMA,25 all included the same 2 small, older RCTs in adults
with active CD.27,28 Meta-analyses of these 2 trials (n ¼
263), yielded a marginal benefit over placebo: RR for failure
to achieve remission, 0.83 (95% CI, 0.69–1.00),23 and RR for
induction of remission, 1.38 (95% CI, 1.00–1.89).24
The NMA, also reported that sulfasalazine was not su-
perior to placebo (OR, 1.50; 95% credible interval, 0.71–
3.12).25 Both of the original RCTs reported significant ben-
efits with sulfasalazine only in the subgroup of patients with
disease confined to the colon, however, the sample sizes
were very small.27,28
No RCTs were found in pediatric patients, and while
mild disease was analyzed separately, the subgroup of pa-
tients was very small.
The quality of evidence was downgraded to very low due
to serious risk of bias, serious indirectness with respect to
populations (lack of pediatric data and inability to separate
mild from moderate disease), and very serious imprecision.
Discussion. As was the case in Statement 1, the
consensus group concluded that there was insufficient evi-
dence to warrant routine use of sulfasalazine in pediatric
patients with moderate disease. Although the statement
suggested against sulfasalazine, it was conditional because
Statement 3: In patients with Crohn’s disease in clinical
remission, we recommend against sulfasalazine or
5-aminosalicylic acid to maintain clinical remission.
GRADE: Strong recommendation, very-low-quality
evidence.
Vote: strongly agree, 33%; agree, 47%; neutral, 20%.
No consensus C: In patients with mild Crohn’s disease
who have achieved clinical remission with sulfasalazine
or 5-aminosalicylic acid, the consensus group does not
make a recommendation (for or against) regarding
continuing sulfasalazine or 5-aminosalicylic acid to
maintain clinical remission.
Key evidence. The data for sulfasalazine and mesal-
amine for maintenance of remission included 2
SR&MAs,23,30 one of which30 included 1 RCT in pediatric
patients.31 Using different eligibility criteria, 1 meta-analysis
included 16 RCTs (n ¼ 2496)23 and the other 12 RCTs (n ¼
2146).30 Sulfasalazine was not effective in preventing
relapse of CD (n ¼ 4 studies; RR, 0.98; 95% CI, 0.82–1.17),
but there was a non-significant trend toward improvement
over placebo with mesalamine (n ¼ 11 studies; RR, 0.94;
95% CI, 0.87–1.01).23 A meta-analysis of data from 12
maintenance trials showed no significant difference in the
RR of adverse events between mesalamine and placebo (RR,
1.08; 95% CI, 0.87–1.34).23
A pediatric RCT in 132 patients reported no statistically
significant difference in relapse rates at 12 months31 with
mesalamine compared to placebo (74% vs 69%; RR, 1.07;
95% CI, 0.86–1.3330).
The reviewed studies did not include analyses assessing
efficacy according to baseline disease severity or treatment
used for induction.
The quality of evidence was downgraded to very low due
to serious risk of bias and very serious imprecision.
Discussion. Evidence suggests that 5-ASA and sulfa-
salazine are generally not effective for maintenance therapy,
therefore, the consensus group made a strong recommen-
dation against their use for most patients who have ach-
ieved remission.
However, a per-protocol analysis found a significant
benefit of mesalamine for the reduction of risk of relapse (RR,
0.79; 95% CI, 0.66–0.95).23 Therefore, the consensus group
questioned whether these agents would be useful as
of the trend toward efficacy in colonic disease, which is the 
location targeted by sulfasalazine. Similar to 5-ASA, given 
the potential efficacy of sulfasalazine in mild disease and the 
fact that treatment delays may be of less concern in such 
patients, the consensus group did not make a recommen-
dation for or against its use in patients with mild colonic 
disease. Some participants argued that it is one of the 
few products that are available in a suspension, and 
recommending against a potentially effective treatment 
would limit the options available for some children who are 
unable to swallow capsules or tablets. However, others 
argued that the adverse events, albeit rare, may not be 
benign, and can include allergic reactions, agranulocytosis, 
and hepatitis.29maintenance therapy in patients whose remission had been
induced with 5-ASA or sulfasalazine. There are few data to
inform amaintenance strategy in such patients; it is unknown
whether the best strategy would be to continue these agents,
provide nomaintenance therapy, or switch to amore effective
medication. In most of the trials, the agents used to achieve
remissionwere not specified, but in 1RCT that used 5-ASA for
induction, there was no significant benefit with continued
5-ASA maintenance therapy.32 The consensus group did not
make a recommendation for or against this strategy.Antibiotics
No consensus D: In patients with mild to moderate
Crohn’s disease, the consensus group does not make a
recommendation (for or against) regarding the use of
antibiotics to induce clinical remission.
No consensus E: In patients with mild to moderate
Crohn’s disease, the consensus group does not make a
recommendation (for or against) regarding the use of
antibiotics to maintain clinical remission.
Key evidence. Two SR&MAs of RCTs have evaluated
the efficacy of antibiotics for induction of remission in pa-
tients with CD.33,34 While there was a significant benefit of
antibiotics overall in inducing remission (n ¼ 10 studies; RR
for failure to achieve remission, 0.85; 95% CI, 0.73–0.99),
the benefit was largely due to positive studies with rifaximin
(n ¼ 2 studies; RR for failure to achieve remission, 0.81;
95% CI, 0.68–0.97).33 The RCTs in these meta-analyses used
a variety of antibiotics and doses, therefore no conclusions
could be drawn for specific antibiotic regimens, with the
exception of rifaximin. There were no serious adverse
events, and no significant differences in adverse events
between rifaximin and placebo.35,36
The quality of evidence was downgraded to very low due
to serious risk of bias, serious indirectness with respect to
populations (lack of pediatric data) and interventions
(diverse regimens), and serious imprecision.
Two SR&MAs assessed the efficacy of antibiotics for the
maintenance of remission in patients with quiescent CD.33,37
All of the RCTs included in these analyses assessed the effi-
cacy of anti-mycobacterial therapies either alone or in com-
bination. Themost recent SR&MA including 4 RCTs (n¼ 206)
found that antibiotics significantly reduced the risk of relapse
compared to placebo in patients with quiescent CD (RR, 0.58;
95% CI, 0.45–0.75).37 The anti-mycobacterial therapies were
associated with a greater risk of adverse events compared to
placebo (RR, 2.57; 95% CI, 1.45–4.55).37 The most common
adverse events included increased skin pigmentation and
rashes. One additional RCT, which did not include an anti-
mycobacterial agent, reported a statistically greater rate of
maintenance of clinical remission at 48 weeks with rifaximin
compared to placebo (71% vs 53%; P < .05).38
The majority of both induction and maintenance RCTs
had small sample sizes, and no RCTs were found that
included pediatric patients.
Table 1.Summary of Consensus Recommendations for the Management of Pediatric Crohn’s Diseasea
Aminosalicylates
Recommendation 1: In patients with moderate CD, we recommend against the use of 5-ASAs to induce clinical remission.
GRADE: Strong recommendation, very-low-quality evidence.
Vote: strongly agree, 67%; agree, 33%.
Recommendation 2: In patients with moderate CD limited to the colon, we suggest against the use of sulfasalazine to induce clinical remission.
GRADE: Conditional recommendation, very-low-quality evidence.
Vote: strongly agree, 67%; agree, 20%; neutral, 7%; disagree, 0%; strongly disagree, 7%.
Recommendation 3: In patients with CD in clinical remission, we recommend against sulfasalazine or 5-aminosalicylic acid to maintain
clinical remission.
GRADE: Strong recommendation, very-low-quality evidence.
Vote: strongly agree, 33%; agree, 47%; neutral, 20%.
Budesonide
Recommendation 4: In patients with mild to moderate ileal and/or right colonic CD, we suggest oral controlled ileal release budesonide to
induce clinical remission.
GRADE: Conditional recommendation, very-low-quality evidence.
Vote: strongly agree, 33%; agree, 67%.
Recommendation 5: In patients with CD, we recommend against oral controlled ileal release budesonide to maintain clinical remission.
GRADE: Strong recommendation, very-low-quality evidence.
Vote: strongly agree, 87%; agree, 13%.
Corticosteroids
Recommendation 6: In patients with moderate to severe CD, we suggest conventional corticosteroids (eg, prednisone) to induce clinical
remission.
GRADE: Conditional recommendation, very-low-quality evidence.
Vote: strongly agree, 47%; agree, 53%.
Recommendation 7: In patients with mild to moderate active CD despite use of sulfasalazine, 5-ASA, oral budesonide, or exclusive enteral
nutrition, we suggest oral prednisone to induce clinical remission.
GRADE: Conditional recommendation, moderate-quality evidence.
Vote: strongly agree, 33%; agree, 67%.
Recommendation 8: In patients with CD of any severity, we recommend against oral corticosteroids to maintain clinical remission.
GRADE: Strong recommendation, low-quality evidence.
Vote: strongly agree, 100%.
Exclusive enteral nutrition
Recommendation 9: In patients with CD, we suggest exclusive enteral nutrition to induce clinical remission.
GRADE: Conditional recommendation, very-low-quality evidence (for pediatrics).
Vote: strongly agree, 33%; agree, 67%.
Recommendation 10: In patients with CD, we recommend against partial enteral nutrition to induce clinical remission.
GRADE: Strong recommendation, very-low-quality evidence.
Vote: strongly agree, 80%; agree, 20%.
Recommendation 11: In patients with CD in remission, we suggest that if partial enteral nutrition is used it should be combined with other
medications to maintain clinical remission.
GRADE: Conditional recommendation, very-low-quality evidence.
Vote: strongly agree, 13%; agree, 87%.
Immunosuppressants
Recommendation 12: In patients with CD of any severity, we recommend against thiopurine monotherapy to induce clinical remission.
GRADE: Strong recommendation, very-low-quality evidence.
Vote: strongly agree, 87%; agree, 13%.
Recommendation 13: In female patients with CD we suggest a thiopurine to maintain remission.
GRADE: Conditional recommendation, low-quality evidence.
Vote: strongly agree, 20%; agree, 73%; neutral, 7%.
Recommendation 14: In patients with CD, we suggest that testing for TPMT by genotype or enzymatic activity be done prior to initiating
thiopurine therapy to guide dosing.
GRADE: Conditional recommendation, very-low-quality evidence.
Vote: strongly agree, 27%; agree, 67%; neutral, 7%.
Recommendation 15: In patients with CD we suggest parenteral methotrexate to maintain clinical remission.
GRADE: Conditional recommendation, low-quality evidence.
Vote: strongly agree, 40%; agree, 60%.
Recommendation 16: In patients with CD who are in clinical remission with a thiopurine or methotrexate as maintenance therapy, we
suggest assessment for mucosal healing within the first year to determine the need to modify therapy if significant ulcerations persist.
GRADE: Conditional recommendation, very-low-quality evidence.
Vote: strongly agree, 13%; agree, 80%; neutral, 7%.
Anti-TNF biologic therapies
Recommendation 17: In patients with moderate to severe inflammatory CD who have failed to achieve clinical remission with corticosteroids,
we recommend anti-TNF therapy (adalimumab, infliximab) to induce and maintain clinical remission.
GRADE: Strong recommendation, high-quality evidence.
Vote: strongly agree, 100%.
Table 1. Continued
Recommendation 18: In patients with moderate to severe inflammatory CD who fail to achieve or maintain clinical remission with a thiopurine
or methotrexate, we recommend anti-TNF therapy to induce and maintain clinical remission.
GRADE: Strong recommendation, high-quality evidence.
Vote: strongly agree, 93%; agree, 7%.
Recommendation 19: In patients with severe inflammatory CD judged at risk for progressive, disabling disease, we suggest anti-TNF therapy
as first-line therapy to induce and maintain clinical remission.
GRADE: Conditional recommendation, very-low-quality evidence.
Vote: strongly agree, 47%; agree, 53%.
Recommendation 20: When starting infliximab in males, we suggest against using it in combination with a thiopurine.
GRADE: Conditional recommendation, low-quality evidence.
Vote: strongly agree, 40%; agree, 47%; neutral, 13%.
Recommendation 21: When starting adalimumab in males, we suggest against using it in combination with a thiopurine.
GRADE: Conditional recommendation, very-low-quality evidence.
Vote: strongly agree, 40%; agree, 53%; neutral, 7%.
Recommendation 22: In male patients with CD receiving immunomodulator therapy in combination with an anti-TNF therapy, we suggest
methotrexate in preference to thiopurines.
GRADE: Conditional recommendation, very-low-quality evidence.
Vote: strongly agree, 27%; agree, 53%; neutral, 20%.
Recommendation 23: In patients with CD who have a suboptimal clinical response to anti-TNF induction therapy or loss of response to
maintenance therapy, we suggest regimen intensification informed by therapeutic drug monitoring.
GRADE: Conditional recommendation, very-low-quality evidence.
Vote: strongly agree, 53%; agree, 47%.
Non–anti-TNF biologic therapies
Recommendation 24: In patients with moderate to severe CD who fail to achieve or maintain clinical remission with anti-TNF–based therapy,
we suggest ustekinumab to induce and maintain clinical remission.
GRADE: Conditional recommendation, moderate-quality evidence for induction, low-quality evidence for maintenance.
Vote: strongly agree, 47%; agree, 53%
Alternative therapies
Recommendation 25: In patients with CD, we recommend against cannabis or derivatives to induce or maintain remission.
GRADE: Strong recommendation, very-low-quality evidence.
Vote: strongly agree, 87%; agree, 7%; neutral, 7%.
Statements with no recommendations
No consensus A: In patients with mild CD, the consensus group does not make a recommendation (for or against) regarding the use of 5-ASAs
to induce clinical remission.
No consensus B: In patients with mild CD limited to the colon, the consensus group does not make a recommendation (for or against)
regarding the use sulfasalazine to induce clinical remission.
No consensus C: In patients with mild CD who have achieved clinical remission with sulfasalazine or 5-ASA, the consensus group does not
make a recommendation (for or against) regarding continuing sulfasalazine or 5-ASA to maintain clinical remission.
No consensus D: In patients with mild to moderate CD, the consensus group does not make a recommendation (for or against) regarding the
use of antibiotics to induce clinical remission.
No consensus E: In patients with mild to moderate CD, the consensus group does not make a recommendation (for or against) regarding the
use of antibiotics to maintain clinical remission.
No consensus F: In male patients with CD the consensus group does not make a recommendation (for or against) regarding a thiopurine to
maintain remission.
No consensus G: In patients with mild to moderate CD, the consensus group does not make a recommendation (for or against) regarding
methotrexate monotherapy to induce clinical remission.
No consensus H: In patients with CD, the consensus group does not make a recommendation (for or against) regarding oral methotrexate to
maintain clinical remission.
No consensus I: In patients with moderate to severe inflammatory CD who have achieved clinical remission but not mucosal healing with a
corticosteroid, thiopurine, or methotrexate, the consensus group does not make a recommendation (for or against) regarding anti-TNF
therapy to induce and maintain mucosal healing.
No consensus J: When starting infliximab in females, the consensus group does not make a recommendation (for or against) regarding
combining it with a thiopurine to maintain a durable clinical remission.
No consensus K: When starting adalimumab in females, the consensus group does not make a recommendation (for or against) regarding
combining it with a thiopurine to maintain a durable clinical remission.
No consensus L: In patients with CD who have achieved a clinical remission with anti-TNF therapy, the consensus group does not make a
recommendation (for or against) regarding assessment for mucosal healing within the first year to determine the need to modify therapy.
No consensus M: In patients with moderate to severe CD who fail to achieve or maintain clinical remission with an anti-TNF–based therapy, the
consensus group does not make a recommendation (for or against) regarding the use vedolizumab to induce and maintain clinical
remission.
aThe strength of each recommendation was assigned by the consensus group, per the GRADE system, as strong (“we
recommend...”) or conditional (“we suggest...”). A recommendation could be classified as strong despite low-quality evidence
to support it, or conditional despite the existence of high-quality evidence due to the 4 components considered in each
recommendation (risk to benefit balance, patients’ values and preferences, cost and resource allocation, and quality of
evidence).
The quality of evidence was downgraded to very low due 
to serious risk of bias, serious indirectness with respect to 
populations (lack of pediatric data), interventions (vari-
ability in antibiotic regimens), and outcomes (definitions of 
relapse), and serious imprecision.
Discussion. A variety of antibiotic regimens were used 
in the trials, which makes interpretation difficult.33,34 This is 
further complicated by the fact that, with the exception of 
rifaximin, the majority of patients were also receiving cor-
ticosteroids and other medications. While the data sup-
ported the efficacy of antibiotics overall for induction of 
remission in meta-analyses, this result was mainly driven by 
rifaximin.33,34 In addition, anti-mycobacterial therapies have 
demonstrated efficacy as maintenance therapy.33,37
However, group members expressed substantial concern 
about the potential development of antibiotic resistance as 
well as cost, particularly when used for maintenance ther-
apy. No serious adverse events were reported in the trials, 
but long-term complications were not reported.37 In addi-
tion, there were no pediatric studies, and no safety data in 
children.
Although antibiotics play a role in the management of 
perianal and postoperative CD, their role in luminal disease 
remains poorly defined. The consensus group concluded 
that there are insufficient data to fully evaluate whether the 
potential benefit (very low quality of evidence suggesting 
efficacy) outweighs the potential risk (adverse effects and 
antimicrobial resistance) and therefore, did not make a 
recommendation for or against the use of antibiotics for 
induction or maintenance therapy.Statement 4: In patients with mild to moderate ileal
and/or right colonic Crohn’s disease, we suggest
oral controlled ileal release budesonide to induce
clinical remission.
GRADE: Conditional recommendation, low-quality
evidence.
Vote: strongly agree, 33%; agree, 67%.
Key evidence. Evidence for the efficacy of budesonide
compared to placebo in inducing clinical remission in pa-
tients with mild to moderate ileal and/or right colonic CD
was available from 3 SR&MAs.39–41 and an NMA.25 In a
meta-analysis of 3 RCTs in adults, budesonide 9 mg/d was
twice as likely to induce remission vs placebo (RR, 1.93;
95% CI, 1.37–2.73; 3 RCTs).41 A lower dose of budesonide
(3 mg/d) was not superior to placebo.40,41 Budesonide was
significantly less effective than conventional corticosteroids
for induction of remission (RR, 0.85; 95% CI, 0.75–0.97; 8
RCTs), but was associated with fewer adverse events (RR,
0.64; 95% CI, 0.54–0.76).41 There was no significant dif-
ference between budesonide and mesalamine (2 RCTs).41
The NMA reported similar results.25
Three small RCTs were conducted in pediatric patients;
2 reported comparable clinical remission rates between
budesonide and prednisone,42,43 while the other found no
Budesonidesignificant difference in remission rates between high-dose
and standard-dose budesonide.44 Adverse events, such as
Cushingoid facies, acne, and myopathy, were more common
with conventional corticosteroids compared to budeso-
nide.42,43 Overall, the quality of evidence was downgraded
to low due to serious risk of bias and serious imprecision.
These RCTs used the oral controlled ileal release prep-
aration or the pH-dependent release formulation, and no
studies that used budesonide MMX for the treatment of CD
were found.
Discussion. A meta-analysis of RCT data in adult and
pediatric patients has shown that budesonide is more
effective than placebo, but less effective than conventional
corticosteroids.41 The more limited pediatric-specific data
are underpowered to identify this treatment inferiority of
budesonide compared with conventional corticoste-
roids.42,43 In both adult and pediatric patients, budesonide
was associated with fewer adverse events, and suppression
of adrenal function was also less frequent, but was still re-
ported with budesonide.42,45 In an RCT in pediatric patients,
mean morning plasma cortisol concentration was signifi-
cantly higher with budesonide compared to prednisolone
after 8 weeks.42 However, in non-IBD studies of budesonide,
morning cortisol concentration was demonstrated to be less
sensitive in identifying adrenocortical suppression
compared with ACTH-stimulation test.46
The consensus group suggested the use of budesonide
based on clinical remission rates in comparative clinical
trials of budesonide vs conventional oral corticosteroids in
adults and children, and in trials of budesonide vs placebo in
adults, as well as in light of the superior safety and tolera-
bility profile of budesonide compared to conventional cor-
ticosteroids. However, this was a conditional suggestion
because budesonide was less effective and more costly than
conventional corticosteroids.
Statement 5: In patients with Crohn’s disease, we
recommend against oral controlled ileal release
budesonide to maintain clinical remission.
GRADE: Strong recommendation, very low-quality
evidence.
Vote: strongly agree, 87%; agree, 13%.
Key evidence. Two SR&MAs found no significant dif-
ference between budesonide and placebo for prevention of
relapse or maintenance of remission in patients with
quiescent CD.39,47 In a meta-analysis of 5 RCTs, budesonide
6 mg/d was no more effective than placebo for maintenance
of remission at 6 months (RR, 1.15; 95% CI, 0.95–1.39) or
12 months (RR, 1.13; 95% CI, 0.94–1.35).47 However, an
NMA showed that budesonide 6 mg/d was superior to
placebo (OR, 1.69; 95% CI, 1.05–2.75).40 For maintenance of
remission there was no statistically significant difference
between budesonide and azathioprine, but budesonide 6 mg
was superior to mesalamine 3 g/d.47
The risk of corticosteroid-related adverse events was
significantly higher with budesonide compared to placebo
(RR, 2.19; 95% CI, 1.08–4.46).39 A meta-analysis of main-
tenance RCTs found significantly higher rates of adrenal
suppression with budesonide compared to placebo.47 In 
addition, a higher incidence of endocrine disorders, mainly 
due to a higher rate of Cushingoid symptoms, has been re-
ported with budesonide.48 A small, non-comparative, pedi-
atric, cohort study also reported a high incidence of adverse 
events (74.0%) with budesonide.45
The RCTs included in these analyses pooled studies us-
ing oral controlled ileal release preparation and the pH-
dependent release formulation. RCTs had small sample 
sizes, low event rates, and no maintenance RCTs in pediatric 
patients were found.
Discussion. The majority of the evidence from RCTs in 
adults fails to show benefit of budesonide over placebo for 
maintenance therapy. RCTs in pediatric patients were not 
found. In an observational pediatric study, maintenance 
therapy with budesonide was associated with a significant 
worsening of disease activity over 12 weeks of treatment.45 
As discussed in Statement 4, adrenal suppression in chil-
dren is of concern.42,45 In addition, in a cohort study, sub-
normal growth velocity was reported during up to 1 year of 
treatment.49
Based on the lack of demonstrated efficacy and the po-
tential for negative long-term effects, including adrenal 
suppression and impaired linear growth, the consensus 
group strongly recommended against the use of budesonide 
for maintenance therapy in pediatric patients.Statement6: Inpatientswithmoderate tosevereCrohn’s
disease, we suggest conventional corticosteroids (eg,
prednisone) to induce clinical remission.
GRADE: Conditional recommendation, very-low-quality
evidence.
Vote: strongly agree, 47%; agree, 53%.
Key evidence. Evidence for the efficacy of oral corti-
costeroids over placebo was derived from 2 positive RCTs
in adults,27,28 which have been included in 2 SR&MAs39,50
and an NMA.25 In the meta-analysis, which used failure to
achieve remission as the primary outcome, there was no
significant benefit of corticosteroids over placebo (RR,
0.46; 95 % CI, 0.17–1.28).39 However, the SR&MA and the
NMA both found that corticosteroids were significantly
more effective than placebo for induction of symptomatic
remission (SR&MA: RR, 1.99; 95% CI, 1.51–2.64;50 NMA:
OR, 3.64; 95% credible interval, 2.16–6.19,25 respectively).
Corticosteroids were associated with higher rates of
adverse events than placebo (RR, 4.89; 95% CI, 1.98–
12.07).50
One small RCT assessed corticosteroids vs exclusive
enteral nutrition (EEN) therapy in pediatric patients and
found no difference in clinical remission rates between the 2
active treatments.51
The quality of evidence was downgraded to very low due
to serious risk of bias, serious indirectness with respect to
comparisons (lack of placebo controlled pediatric data), and
serious imprecision.
CorticosteroidsDiscussion. Although the data are very low quality,
corticosteroids appear to be more effective than placebo for
induction of remission in adults with CD. In pediatric pa-
tients, there were no placebo-controlled RCTs, however,
conventional corticosteroids appeared to be as effective as
budesonide and EEN in several small RCTs.42,43,51
Based on evidence suggesting efficacy, and the fact that
this is an inexpensive treatment option, the consensus
group suggested conventional corticosteroids for short-term
use for induction of remission. However, this statement was
a conditional recommendation because of the potential
negative consequences of delaying the use of other options
with greater efficacy, as well as the adverse event profile of
corticosteroids, which is of greater concern in children than
in adults. Systemic corticosteroids (even short-term use)
should be used with particular caution in patients with
linear growth delay, osteoporosis, or mental health
disorders.
Statement 7: In patients with mild to moderate active
Crohn’s disease despite use of sulfasalazine, 5-
aminosalicylate, oral budesonide, or exclusive
enteral nutrition, we suggest oral prednisone to
induce clinical remission.
GRADE: Conditional recommendation, moderate-quality
evidence.
Vote: strongly agree, 33%; agree, 67%.
Key evidence. The evidence for the efficacy of sys-
temic corticosteroids compared to placebo was discussed in
Statement 6. In addition, RCTs comparing conventional
corticosteroids and budesonide were considered. As
described in Statement 4, conventional corticosteroids were
significantly more effective than budesonide for induction of
remission in a meta-analysis of 8 trials.41 The 2 small RCTs
that compared prednisolone with budesonide in pediatric
patients were inadequately powered to demonstrate a
treatment benefit.42,43 The quality of evidence was down-
graded to moderate due to serious risk of bias. However, it
was not downgraded for imprecision, inconsistency, or
indirectness in relation to populations due to the availability
of limited data from pediatric populations.
Discussion. Although less adequately examined in
children, conventional corticosteroids have been shown to
be more effective than budesonide and 5-ASA in adults.25,41
In an SR&MA conducted for this consensus, conventional
corticosteroids were more effective than EEN in adults,
whereas both treatments were equally effective in pediatric
patients with comparatively shorter duration of CD
(frequently new onset) (see Statement 9). The data sup-
porting superior efficacy of conventional corticosteroids in
head-to-head trials suggest that patients have a greater
likelihood of responding, and thus may benefit from these
agents after failure of budesonide, 5-ASA, or EEN. Efficacy
directly after other treatment failures, however, has not
been assessed specifically. Therefore, the consensus group
made a conditional suggestion in favor of the use of con-
ventional corticosteroids as a second-line treatment option
for induction of remission.
Statement 8: In patients with Crohn’s disease of any
severity, we recommend against oral corticosteroids
to maintain clinical remission.
GRADE: Strong recommendation, low-quality evidence.
Vote: strongly agree, 100%.
Key evidence. A meta-analysis including 3 RCTs found
no significant reduction in the odds of relapse with ongoing
corticosteroid therapy compared to placebo (12-month OR,
0.82; 95% CI, 0.47–1.44).52 In addition, attrition was high,
with only about 36% of patients available for the 12-month
analysis, primarily due to adverse events.
The quality of evidence was downgraded to low due to
serious risk of bias and serious imprecision. However, it was
not downgraded for indirectness with respect to pop-
ulations due to the availability of limited data from pediatric
populations.
Discussion. The consensus group made a strong
recommendation against the use of corticosteroids for main-
tenance therapy because of the lack of demonstrated efficacy
in preventing relapse and concerns around the adverse events
associated with long-term use, particularly in children.Exclusive enteral nutrition
Statement 9: In patients with Crohn’s disease, we
suggest exclusive enteral nutrition to induce clinical
remission.
GRADE: Conditional recommendation, very low-quality
evidence.
Vote: strongly agree, 33%; agree, 67%.
Key evidence. Seven SR&MAs have been published
that evaluated studies comparing EEN to corticosteroids for
induction of clinical remission in adult,53–55 pediatric,56–58
or a mixed population of patients with CD.59 Due to limi-
tations of these previous SR&MAs, an updated SR&MA was
conducted to inform the development of this guideline.
The SR&MA conducted for this meeting included only
RCTs published in full that compared EEN with placebo or
other active treatments in patients with active CD. No
placebo-controlled trials were identified. The MA included 9
RCTs (2 pediatric51,60 and 7 adult trials61–67) comparing
EEN with corticosteroids in 435 patients (57 pediatric and
378 adult patients). EEN was inferior to corticosteroids for
induction of remission in the combined (OR, 0.43; 95% CI,
0.22–0.87) and adult patient populations (OR, 0.27; 95% CI,
0.17–0.43). In the 57 pediatric patients randomized, there
was no significant difference in clinical remission rates be-
tween EEN and corticosteroids (83% vs 61%; OR, 3.04, 95%
CI, 0.73–12.65). There was no significant difference in the
incidence of adverse events between EEN and corticoste-
roids (21% vs 30%; OR, 0.41; 95% CI, 0.15–1.09). All
adverse events were minor and included nausea, vomiting,
abdominal pain, and diarrhea with EEN, and Cushingoid
facies and acne with corticosteroids. However, the more
serious adverse effects of steroids (eg, osteoporosis, growthfailure, adrenal suppression) were not evaluated in these
trials. EEN was associated with significantly higher with-
drawal rates than corticosteroids in the adult RCTs (OR,
6.57; 95% CI, 2.24–19.24), but not in the pediatric RCTs
(OR, 0.59; 95% CI, 0.09–4.01).
There was wide variation in disease activity, onset of
disease, disease location, study designs, methods used to
define disease activity and remission, duration of in-
terventions, length of follow-up, and use of concomitant
medication. In addition, due to the nature of the interven-
tion, blinding was not possible.
In the combined population, the overall quality of evi-
dence for the outcome of clinical remission was very low
against the use of EEN, however, in the pediatric population,
the evidence was very low in support of the use of EEN. The
quality of evidence was downgraded to very low due to
serious risk of bias, serious inconsistency, serious indirect-
ness with respect to disease activity, onset of disease, and
disease location, as well as variations in the types of enteral
formula used and the use of concomitant medications, and
serious imprecision.
Discussion. There were very-low-quality data showing
that EENwas less effective than corticosteroids in a combined
population of adults and pediatric patients. However, in 2
very small trials of pediatric patients alone, no difference in
clinical remission rates with EEN vs corticosteroids was
demonstrated. Most pediatric studies included newly diag-
nosed patients, whereas adult clinical trials have been con-
ducted among patients with a much longer time since
diagnosis. No placebo-controlled RCTs were found, and the
available data suggested that at least in pediatric patients,
EENwas as effective as an active therapy (corticosteroids) for
the induction of remission (see Statement 6). In the pediatric
trials, mucosal healing rates with EEN were significantly
greater than those with corticosteroids, however, there were
limitations, such as small numbers of participants and lack of
blinding or allocation concealment.51,60
Withdrawal rates were high in the adult studies, but not
in the pediatric trials. Adverse events with EEN were
generally minor, and mainly gastrointestinal in nature.
Under-nutrition in children with CD, although less
important than direct effects of pro-inflammatory cytokines
released from inflamed intestine, can contribute to impair-
ment of growth and pubertal development.7,68 Use of EEN
restores a normal nutritional status and avoids corticoste-
roid use, which may also impede linear growth.69 Growth
data reported in one of the pediatric EEN RCTs showed a
significant improvement in weight gain with EEN compared
to corticosteroids, but no difference in height gain.51
Protocols for EEN therapy varied with respect to specific
formula used (although usually polymeric), mode of
administration (nocturnally via nasogastric tube or via oral
drinking), allowance of clear fluids other than water during
treatment, and duration of therapy.70 One RCT71 and 1
prospective study72 found EEN (defined as 100% EN) to be
more effective than partial EN (PEN; defined as 50% of
calories via EN while eating an unrestricted diet).
Shorter duration of CD among children vs adults
included in clinical trials, as well as better adherence, may
Statement 10: In patients with Crohn’s disease, we
recommend against partial enteral nutrition to induce
clinical remission.
GRADE: Strong recommendation, very-low-quality
evidence.
Vote: strongly agree, 80%; agree, 20%.
Key evidence. No RCTs comparing PEN to placebo or
any active therapy (including steroids and immunosup-
pressants) were found. In 1 RCT in 50 children with active
CD, PEN was less effective than total EN for the induction of
clinical remission (15% vs 42%; P ¼ .035).71 This yielded an
OR of 0.25 (95% CI, 0.07‒0.97), but the CIs were very wide.
Similarly, in a recent multicenter North American study,
patients allowed 20% of total calories as regular food
actually consumed 50% of calories as such, and were less
likely to achieve either clinical remission or reduction in
fecal calprotectin compared with those receiving EEN.72 The
quality of evidence was downgraded to very low due to
serious risk of bias, serious inconsistency, very serious
indirectness with respect to the interventions, and serious
imprecision.
Discussion. PEN has been shown to be inferior to EEN.
Similar to EEN, a protocol for PEN is poorly defined, and it is
unknown what ratio of formula to oral food would be effi-
cacious, if any.
The consensus group made a strong recommendation
against the use of PEN for induction therapy based on the
lack of efficacy, and concerns that using PEN will cause
further delays in use of treatments with demonstrated
efficacy.
Statement 11: In patients with Crohn’s disease in
remission, we suggest that if partial enteral nutrition
is used it should be combined with other medications
to maintain clinical remission.
GRADE: Conditional recommendation, very low-quality
evidence.
Vote: strongly agree, 13%; agree, 87%.
explain the better results in the SR&MA of pediatric RCTs 
compared to RCTs in adults. In clinical practice, EEN is 
generally attempted early as first-line therapy in patients 
with new-onset CD.8
Nutrition is important in children with CD, and, based on 
similar efficacy and better safety compared to corticoste-
roids in the pediatric RCTs, the consensus group suggested a 
course of EEN for induction of remission was a reasonable 
first-line treatment strategy in pediatric patients, although 
the group concluded that there was not enough evidence to 
define the required duration of therapy. However, this 
statement was a conditional suggestion due to the conflict-
ing evidence in adults, and the very small number of chil-
dren included in individual pediatric RCTs, most of which 
had a high risk of bias. Moreover, reimbursement of formula 
in many Canadian jurisdictions has, until recently, required 
that the formula be administered via nasogastric tube. The 
inconvenience of such enteral feeding has been a major 
barrier to acceptance.Key evidence. An SR found 3 RCTs that assessed the
efficacy of PEN to maintain remission in adults with
quiescent CD.73 Due to substantial differences in study
designs, a meta-analysis was not performed. The trials
compared PEN to regular diet alone in 1 study (with
concomitant 5-ASA in both groups, and azathioprine
permitted), to 6-mercaptopurine in 1 study (with
concomitant 5-ASA in both treatment groups), and to 5-
ASA plus regular diet in 1 study (with no concomitant
therapy). There were substantial variations in the type and
duration of EN and the duration of follow-up. All 3 RCTs
concluded that PEN was similar to the comparator groups
(regular diet with or without medication) for maintenance
of clinical remission.
The majority of reported adverse events were mild and
mainly gastrointestinal (ie, diarrhea, abdominal cramps,
nausea, and vomiting). Intolerance and lack of compliance
due to taste or smell of the formula were also reported.73
The RCTs included in this SR were very heterogeneous,
had small sample sizes, low event rates, and none included
pediatric patients.
The quality of evidence was downgraded to very low due
to serious risk of bias, very serious indirectness with respect
to the populations, interventions or comparators, and
serious imprecision.
Discussion. The evidence for PEN maintenance ther-
apy was very low quality, and in 2 of the 3 trials, PEN was
used in combination with medications in Asian patients.
Therefore, generalizability to other populations may be
limited.
The SR73 included 2 observational studies in pediatric
patients.74,75 In 1 retrospective study, maintenance PEN
alone was more effective than no treatment, but less effec-
tive than the combination of azathioprine plus PEN. There
were no differences in relapse rates between the combina-
tion of azathioprine plus EN and azathioprine alone.74 In
this study, only 31% of patients completed 8 weeks of EEN
and were able to continue maintenance EN.
Older observational studies have reported improve-
ments in growth with the use of supplementary PEN in
patients also using conventional therapies.73
The consensus group suggested PEN for the mainte-
nance of remission only when used as adjunctive therapy
for patients receiving medications proven to be efficacious.
Although a vote was conducted, both insufficient evidence
and lack of consensus prevented the group from making any
recommendation regarding the use of PEN as sole mainte-
nance therapy.Immunosuppressants
Statement 12: In patients with Crohn’s disease of
any severity, we recommend against thiopurine
monotherapy to induce clinical remission.
GRADE: Strong recommendation, very-low-quality
evidence.
Vote: strongly agree, 87%; agree, 13%.
 
Statement 13: In female patients with Crohn’s disease,
we suggest a thiopurine to maintain remission.
GRADE: Conditional recommendation, low-quality
evidence.
Vote: strongly agree, 20%; agree, 73%; neutral, 7%.
No consensus F: In male patients with Crohn’s disease
the consensus group does not make a recommendation
(for or against) regarding use of a thiopurine to maintain
remission.
Key evidence. Evidence for the efficacy of mainte-
nance thiopurine therapy comes from 2 SR&MAs of RCTs in
adults who had achieved remission, generally with a com-
bination of corticosteroid and thiopurine therapy.77,83 A
meta-analysis of 6 studies found that azathioprine was
significantly superior to placebo in maintaining remission
over 6–18 months (RR, 1.19; 95% CI, 1.05–1.34).83 One
additional small RCT withdrawal trial, published after the
meta-analyses, also reported a reduction in risk of relapse
with ongoing thiopurine therapy, which was significant at 1
year, but not at 2 years.84 Because most of the patients in
these studies had achieved remission while on a thiopurine,
they may have been more likely to show a positive effect
with thiopurine maintenance therapy. Thiopurine use was
associated with a 40% (hazard ratio [HR], 0.59; 95% CI,
0.48–0.73) reduction in the risk of first surgical resection in
Key evidence. Two SR&MAs,76,77 which included the 
same 5 RCTs, reported no significant improvement in 
symptomatic remission rates with thiopurine therapy 
(azathioprine or 6-mercaptopurine) compared to placebo 
(RR for failure to achieve remission, 0.87; 95% CI, 0.71–
1.06).77 Four of the 5 studies combined thiopurines with a 
tapering course of steroid therapy during induction; there-
fore, the data demonstrated no additional benefit of
adjunctive thiopurine therapy over steroids alone.
Data on serious adverse events were available from 2 
trials; in the pooled analysis, the incidence was higher with 
thiopurines vs placebo (14% vs 4%), but this was not sta-
tistically significant (RR, 2.57; 95% CI, 0.92–7.13).76
The RCTs included in these SR&MAs had small sample 
sizes, low event rates, and no RCTs were found in pediatric 
patients.
The quality of evidence was downgraded to very low due 
to serious risk of bias, serious indirectness with respect to 
the populations, interventions, or comparators, and serious 
imprecision.
Discussion. RCTs in adults have not shown a signifi-
cant benefit with thiopurines for induction therapy, and no 
pediatric RCTs were found. These agents are slow-acting 
and are associated with poor tolerability (eg, allergic re-
actions, leukopenia, pancreatitis, and nausea76) and safety 
issues (eg, lymphoma, including hepatosplenic T-cell lym-
phoma [HSTCL],78,79 non-melanoma skin cancer,80 and 
myelosuppression81,82). (See also Statements 13 and 14.)
Based on the lack of evidence of beneficial effects, and 
the safety concerns, the consensus strongly recommended 
against use of a thiopurine alone for induction therapy.patients with CD in a meta-analysis of retrospective obser-
vational studies.85
One RCT86 and 1 observational study87 assessed thio-
purine maintenance therapy in pediatric patients. The small
RCT found that, in children receiving corticosteroid therapy,
the addition of 6-mercaptopurine was associated with a
lower rate of relapse compared to adjunctive placebo at 18
months (9% vs 47%; P ¼ .007).86 Thiopurine use was also
associated with decreased use of corticosteroids. In the
observational study, 47% and 23% of pediatric patients
remained in remission with thiopurine therapy at 6 and 12
months, respectively.87
Compared to placebo, azathioprine demonstrated a
significantly greater risk of adverse events (RR, 1.29; 95%
CI, 1.02–1.64) and serious adverse events (RR, 2.45; 95% CI,
1.22–4.90). Common events included pancreatitis, leuko-
penia, nausea, allergic reaction, and infection.83
The quality of evidence was downgraded to very low due
to serious risk of bias, serious indirectness with respect to
the populations, and serious imprecision.
Discussion. Evidence from adult and pediatric RCTs
supports the efficacy of thiopurines for maintenance
therapy. However, thiopurines are associated with tolera-
bility issues,83 and a risk of rare, but serious adverse
outcomes, including lymphoma (eg, HSTCL),78,79 non-
melanoma skin cancers,80 and cervical cancer.88 During
longitudinal surveillance of more than 189,000 IBD pa-
tients for a median of almost 7 years, the risk of lymphoma
among those exposed to thiopurine monotherapy was
increased (adjusted HR, 2.60; 95% CI, 1.96‒3.44; P< .001).
However, the absolute incidence rate of 0.54 (95% CI,
0.41‒0.67) per 1000 person-years was low among patients
exposed to thiopurines. The risk with exposure to thio-
purines and/or anti-TNFs was higher in males than females
(adjusted HR, 1.56; 95% CI, 1.25–1.94), but was elevated in
both groups compared to those without thiopurine expo-
sure.79 In 2014, Health Canada issued an alert warning of
the risk of HSTCL with thiopurines.89 This warning led to a
position statement from the CAG recommending that
continuation of thiopurine therapy consider the benefits
and risks for an individual patient.90
In pediatric patients, the DEVELOP Registry (An In-
flammatory Bowel Disease Multicenter, Prospective, Long-
Term Registry of Pediatric Patients) has been established
to provide post-marketing data on infliximab safety in pe-
diatric patients with CD or ulcerative colitis.91 The registry
identified exposure to thiopurines as increasing the risks of
malignancy compared to Surveillance, Epidemiology, and
End Results Program database age- and sex-matched
healthy peers, and of hemophagocytic lymphohistiocytosis
occurrences in the setting of first exposure to Epstein-Barr
virus.
The consensus group concluded that the evidence for
efficacy suggested that thiopurines were a viable option for
maintenance of remission, but there were safety concerns.
In balancing the concern of teratogenicity with metho-
trexate, the consensus group made a suggestion in favor of
their use in female patients, but this was conditional
because although the risk of lymphoma is higher in males, it
Statement 14: In patients with Crohn’s disease, we
suggest that testing for thiopurine methyltransferase
by genotype or enzymatic activity be done prior to
initiating thiopurine therapy to guide dosing.
GRADE: Conditional recommendation, very low-quality
evidence.
Vote: strongly agree, 27%; agree, 67%; neutral, 7%.
Key evidence. Three RCTs assessed the benefits of
thiopurine methyltransferase (TPMT) testing compared to no
testing before initiating thiopurine therapy to individualize
dosing and thereby minimize the risk of early profound
neutropenia in thosewith low TPMT activity.92–94 Genotyping
was used in 2 studies92,93 and enzymatic activity in 1 study.94
Among the 1145 patients included, only 2 (0.17%) patients
were homozygous, and 150 (13.1%) were heterozygous for
variant alleles in the TPMT gene. A meta-analysis found no
significant improvement with TPMT testing and dose ad-
justments compared to no testing in rates of hematologic
events (RR, 0.94; 95% CI, 0.59–1.50) or treatment discon-
tinuations (RR, 1.10; 95% CI, 0.94–1.27), and dose adjust-
ments did not negatively impact clinical remission rates (RR,
1.03; 95% CI, 0.84–1.27).95 While most patients with leuko-
penia in the largest study did not have reduced enzymatic
activity, individuals with TPMT mutations and low or in-
termediate enzymatic activity had a significant reduction
in the risk of hematologic adverse events with TPMT
testing to guide dosing (RR, 0.11; 95% CI, 0.01–0.85).92
Although specific studies on the role of TPMT testing
(genotype or enzymatic activity) in pediatric patients were
not found, studies suggest that pediatric and adult patients
have similar TPMT activity and similar adverse event
frequencies.96,97
The quality of evidence was downgraded to very low due
to serious risk of bias, serious indirectness (with respect to
the populations), and serious imprecision.
Discussion. Although the incidence of patients with
low or absent levels of TPMT (the enzyme needed to
metabolize thiopurines) is low, these patients can be at risk
of early severe myelosuppression if treated with standard
thiopurine doses.81,82 Of note, data suggest that thiopurines
may be more likely to affect myelosuppression in East Asian
populations than in Caucasian populations regardless of
TPMT expression due to other genetic factors.98 In a meta-
analysis of 7 studies of patients with IBD treated with thi-
opurines, 3.2% developed leukopenia, and 0.09% of patients
died.81 Although rare, leukopenia can result in infectious or
bleeding complications99 and can be rapidly fatal.81,100
Thus, there can be considerable harm associated with us-
ing thiopurines in patients with low or absent TPMT levels.
remains elevated in both sexes. Although a vote was con-
ducted, both safety concerns and lack of consensus pre-
vented the group from making a recommendation regarding 
the use of thiopurine maintenance therapy in male patients. 
Some participants argued that the benefits outweighed the 
risks, while others argued that the potential for life-
threatening adverse events was not acceptable given the 
availability of alternate therapies.The risks of myelosuppression are reportedly highest in
first 8 weeks of treatment,99 but can occur at any time.92–94
In patients with subnormal TMPT activity, clinical trials
have suggested dose adjustments, such as a 50% dose in
patients with intermediate enzymatic activity and even
lower doses or not using thiopurines at all in patients with
low/absent enzyme activity.92–94 TMPT levels in pediatric
patients appear to be similar to those in adults.
In light of the potential life-threatening consequences,
the consensus group suggested TPMT testing (genotype or
enzymatic activity) before initiating thiopurine therapy. This
was a conditional suggestion because of concerns that TPMT
testing may yield a false sense of security, as the majority of
cases of leukopenia are unpredictable and independent of
TPMT enzyme activity. TPMT testing results also do not
correlate with the development of other adverse events,
such as hepatotoxicity or pancreatitis.
Testing can be costly; however, 2 cost-effectiveness an-
alyses in patients with IBD and rheumatoid arthritis,81,101
and a prospective economic evaluation of the TARGET
study,93,102 suggested that TPMT testing (genotype) was a
cost-effective strategy compared to no testing for patients
initiating thiopurine therapy.
No consensus G: In patients with mild to moderate
Crohn’s disease, the consensus group does not make a
recommendation (for or against) regarding methotrexate
monotherapy to induce clinical remission.
Statement 15: In patients with Crohn’s disease, we
suggest parenteral methotrexate to maintain clinical
remission.
GRADE: Conditional recommendation, low-quality
evidence.
Vote: strongly agree, 40%; agree, 60%.
No consensus H: In patients with Crohn’s disease, the
consensus group does not make a recommendation (for
or against) regarding oral methotrexate to maintain
clinical remission.
Key evidence. Methotrexate induction therapy.
Evidence for the efficacy of methotrexate for the induction
of symptomatic remission comes from 1 SR&MA,77 which
included 2 RCTs conducted in adult patients with steroid-
dependent CD. There was no statistically significant
benefit on the outcome of failure to achieve remission (RR,
0.82; 95% CI, 0.65–1.03).77 Although 1 of the RCTs found no
benefit with oral methotrexate,103 the other demonstrated a
significant improvement in remission rates at 16 weeks,
with an intramuscular methotrexate vs placebo (RR, 1.95;
95% CI, 1.09–3.48; P ¼ .025).104 Another SR without meta-
analysis included 4 trials assessing methotrexate vs active
comparators.105 Methotrexate appeared to be as effective as
thiopurines, and more effective than 5-ASA.
Very-low-quality pediatric data were available from an
SR of 10, predominantly retrospective, case series. Short-
term remission rates (3 months) were only reported for
parenteral methotrexate therapy. The remission rate in 1
study was 57% at 1 month and 29% to 70% at 3 months.106
The quality of evidence was downgraded to very low due 
to serious risk of bias, serious indirectness with respect to 
the populations and interventions, and serious imprecision.
Parenteral methotrexate maintenance ther-
apy. Evidence for the efficacy of methotrexate for mainte-
nance therapy in adults with CD in clinical remission was 
available from 2 SR&MAs.77,107 Only 1 trial assessed intra-
muscular methotrexate as maintenance therapy.108 In this 
trial, there was a significant reduction in the risk of relapse 
with methotrexate compared to placebo (RR, 0.57; 95% CI, 
0.35–0.94) in adult patients who had achieved remission 
with a combination of steroid and methotrexate therapy. 
Two other small trials included in the SR&MAs showed no 
significant benefit of oral methotrexate on the risk of 
relapse.103,109
In the SR of pediatric observational studies, long-term 
remission rates were 37% to 62% at 6 months, and 25%
to 53% at 12 months, primarily with parenteral metho-
trexate, although this was switched to oral in some case 
series.106 The lack of a comparator group, varying patient 
populations, interventions, concomitant therapy, and defi-
nitions of remission, make these data difficult to interpret.
Oral methotrexate maintenance therapy. There were 2 
RCTs using oral methotrexate for maintenance therapy, both 
of which demonstrated no significant benefit103,109; how-
ever, there was some question as to whether methotrexate 
was used to induce remission in these trials because pa-
tients had chronic steroid-dependent CD, and may not have 
been in remission.77,107 The only positive maintenance RCT 
was the intramuscular trial.108 If this is extrapolated to 
support the use of the oral form, the evidence would be 
further downgraded to very low quality. In the SR of pedi-
atric data, some patients were switched to oral metho-
trexate, and the case series comparing oral and 
subcutaneous methotrexate reported similar remission 
rates.106 However, these data are likely confounded by 
preferential use of oral therapy in patients with milder 
disease.
Safety. In the intramuscular study, withdrawals due to 
adverse events were significantly more common with 
methotrexate vs placebo (RR, 8.00; 95% CI, 1.09‒59.51).104 
No serious adverse events were reported in the clinical 
trials.
In the SR of pediatric data, adverse events were similar 
to those seen in adults, with the most common adverse 
events being nausea and vomiting.106 In a retrospective 
study, 31% of 102 pediatric patients with IBD experienced 
methotrexate intolerance (gastrointestinal or behavioral 
symptoms).110 Strategies to reduce these effects in children 
have been reported.111 Other adverse events included 
elevated liver function tests, headache, and hematologic 
toxicity.106 Infectious adverse events were also reported 
(upper respiratory tract infection, varicella zoster reac-
tivation).106 An SR&MA of 12 cohort studies assessed the 
incidence of hepatotoxicity among children with IBD taking 
methotrexate. Overall, 10.2% (95% CI, 5.4%‒18.5%) of 
patients had abnormal liver biochemistry and 4.5% (95%, 
CI, 2.8%‒7.2%) of patients required discontinuation of the 
drug.112 As the drug has the potential for teratogenic effects,embryotoxicity, abortion, and fetal defects in humans it
cannot be used in pregnant females, raising significant
concerns in those who provide care when pregnancy is
possible.
The quality of evidence was downgraded to very low due
to serious risk of bias, serious indirectness (with respect to
the populations), and serious imprecision.
Discussion. Significant benefits with methotrexate for
the management of CD are seen only in the 1 RCT, which
used the intramuscular formulation for induction and
maintenance therapy.108 RCTs using oral methotrexate for
induction or maintenance therapy have not shown signifi-
cant benefit. There were no RCTs in pediatric patients, but
the observational data suggested that about 25% to 50% of
patients can achieve long-term remission with subcutane-
ous and/or oral methotrexate.106
Pharmacokinetic data show differences between oral
and parenteral methotrexate,113 and common practice in
rheumatology has included switching from oral to paren-
teral in cases where oral methotrexate was not effective. In
clinical practice, subcutaneous methotrexate is used more
often than intramuscular delivery. The pharmacokinetics of
the subcutaneously administered drug have been shown to
be similar to intramuscular injection.114,115 In addition,
subcutaneous administration minimizes local reactions at
the injection site, and may be more convenient and less
painful.113,114
The RCTs using methotrexate as induction therapy
provided conflicting results; the oral trials were negative,
while the intramuscular trial was positive. Short-term re-
sults from the observational data in pediatric patients were
only available for parenteral methotrexate. Based on these
conflicting data, the consensus group did not make a
recommendation for or against the use of methotrexate for
induction therapy. Participants in support of this strategy
cited the potential efficacy as demonstrated in the intra-
muscular trial, and the observational studies. Because there
are very few treatments for CD, which is a lifelong disease,
methotrexate is a potentially useful treatment that should
not be discarded. Methotrexate has a slow onset of action,
therefore, for patients who are not acutely symptomatic and
in whom a delayed response would be acceptable, it may be
an option to start it in the induction phase in order to use it
as maintenance therapy. Participants who were against
recommending methotrexate for induction therapy argued
that the trials were not monotherapy trials; most patients
were on other therapies (particularly corticosteroids), and
the contribution of methotrexate is uncertain.
Based on evidence supporting beneficial effects of
intramuscular methotrexate, the consensus group suggested
parenteral methotrexate for use as maintenance therapy.
However, there was insufficient evidence to make a
recommendation regarding the use of oral methotrexate in
this setting. While the RCTs using oral methotrexate were
negative, these trials were very small, and the doses used
may have been inadequate. The data from the intramuscular
trial suggest the potential for efficacy with this medication.
Some consensus participants argued that some patients in
stable remission may continue to benefit when switched
Statement 16: In patients with Crohn’s disease who
are in clinical remission with a thiopurine or
methotrexate as maintenance therapy, we suggest
assessment for mucosal healing within the first year
to determine the need to modify therapy if significant
ulcerations persist.
GRADE: Conditional recommendation, very-low-quality
evidence.
Vote: strongly agree, 13%; agree, 80%; neutral, 7%.
No consensus I: In patients with moderate to severe
inflammatory Crohn’s disease who have achieved
clinical remission but not mucosal healing with a
corticosteroid, thiopurine, or methotrexate, the
consensus group does not make a recommendation (for
or against) regarding anti-TNF therapy to induce and
maintain mucosal healing. (Note there was insufficient
evidence at the time of the literature searches, but the
consensus group recognized that this would need
updating as new evidence becomes available).
Key evidence. Observational data (1 SR of cohort
studies, and post-hoc analyses of RCTs) have suggested that
achieving deep remission is associated with improved clin-
ical outcomes, including higher rates of clinical remission,
improved quality of life, and reduced need for steroids,
hospitalizations, and surgery.10,11 The SR&MA of prospec-
tive cohort data, including 12 studies found that patients
who had achieved mucosal healing had significantly
increased rates of long-term clinical remission (OR, 2.80;
95% CI, 1.91‒4.10) and mucosal healing (OR, 14.30; 95% CI,
5.57‒36.74).11 There was a trend to a greater CD-related
surgery-free rate (OR, 2.22; 95% CI, 0.86‒5.69), but this
was not significant.
In pediatric patients, complete mucosal healing was
associated with significantly higher rates of long-term
remission for up to 3 years compared to ongoing active
endoscopic disease.12
Rates of mucosal healing with anti-TNF therapy (27%‒
31%) were higher than those seen with immunosuppres-
sants (16.5%) or placebo (0‒13%).116–118 Combination anti-
TNF and immunosuppressant therapy (43.9%) provided
even higher rates compared to anti-TNF (30.1%; P ¼ .06) or
immunosuppressant therapy (16.5%; P < .001) alone.118 In
addition, a higher rate of mucosal healing with combination
therapy compared to conventional therapy at 2 years (73%
vs 30%; P ¼ .0028)119 was a significant predictor of
remaining in remission at 3 and 4 years (OR, 4.35; 95% CI,
1.10‒17.22).120
Several case series in pediatric patients have reported
rates of mucosal healing associated with anti-TNF therapy.
Complete mucosal healing was seen in 22%‒25% of pa-
tients, and endoscopic improvement in 44%‒67%.121–123
The evidence was downgraded to very low due to serious
risk of bias, serious indirectness with respect to the use of
surrogate outcomes (mucosal healing) and serious imprecision.
from parenteral to lower cost, more convenient, oral 
methotrexate. This is supported by observational data re-
ported in the SR of pediatric studies.106Discussion. There are long-term benefits associated
with mucosal healing. Assessment for mucosal healing
generally requires endoscopy, which is both costly and inva-
sive. Imaging (eg, magnetic resonance enterography) and
biomarker levels (eg, C-reactive protein and fecal calprotectin)
have been shown to correlate with endoscopy,124 and changes
in these parameters were recently shown to correlate with
mucosal healing. The open-label, RCT CALM (published
outside the search window) compared treatment escalation
with an anti-TNF therapy based on both clinical symptoms and
biomarkers (tight control) to symptom-driven decisions alone
(clinical management) in 244 adult patients. At week 48,
significantly more patients in the tight control group achieved
mucosal healing (46%) than in the clinical management group
(30%, risk difference, 16.1%; 95% CI, 3.9‒28.3; P ¼ .010).125
Based on the potential benefits associated with mucosal
healing, the consensus group suggested that assessing this
outcome was a useful management strategy in patients
receiving immunosuppressant therapy. Data suggest higher
mucosal healing rates with anti-TNF therapies and better
long-term outcomes when healing is achieved. The
consensus group, nevertheless, did not make a universal
recommendation regarding switching to or adding an anti-
TNF to therapy in all patients who have achieved clinical
remission but not mucosal healing with immunosuppres-
sant therapy. This was largely related to the fact that the
degree of mucosal healing required to achieve clinically
relevant benefits needs to be more clearly defined. The
REACT-2 trial is underway in adults to assess whether early
treatment intensification based on mucosal healing will
reduce the risk of hospitalization, surgery, and CD compli-
cations compared to conventional step-up therapy.Anti–Tumor Necrosis Factor Biologic Therapy
Statement 17: In patients with moderate to severe
inflammatory Crohn’s disease who have failed to
achieve clinical remission with corticosteroids, we
recommend anti-TNF therapy (adalimumab,
infliximab) to induce and maintain clinical remission.
GRADE: Strong recommendation, high-quality evidence.
Vote: strongly agree, 100%.
Statement 18: In patients with moderate to severe
inflammatory Crohn’s disease who fail to achieve or
maintain clinical remission with a thiopurine or
methotrexate, we recommend anti-TNF therapy to
induce and maintain clinical remission.
GRADE: Strong recommendation, high-quality evidence.
Vote: strongly agree, 93%; agree, 7%.
Key evidence. Anti-TNF therapy has been extensively
studied in double-blind RCTs in adults, which have been
assessed in a number of SRs with or without meta-analy-
ses.126–128 In most of the studies assessing its use to induce
remission, patients had previously received other treat-
ments, including corticosteroids and immunosuppressants,
and analyses according to type of prior treatment were not
performed. For induction therapy, a meta-analysis including 
10 trials found that anti-TNF therapy alone or with 
concomitant therapies was significantly more effective than 
placebo for the outcome of failure to achieve symptomatic 
remission (RR, 0.87; 95 % CI, 0.80–0.94; P ¼ .0004). Results 
were significant for infliximab and adalimumab, but not 
certolizumab pegol.126 For maintenance therapy, meta-
analysis of 5 RCTs showed that anti-TNF therapy signifi-
cantly reduced the risk of relapse in patients with CD in 
clinical remission compared to placebo (RR, 0.71; 95% CI, 
0.65–0.76; P < .00001).126 Results were significant for 
infliximab and certolizumab pegol, but not adalimumab. In 
another meta-analysis, all 3 anti-TNFs were significantly 
more effective than placebo for both induction and main-
tenance of remission.129
In the SR&MA, there were no significant differences in 
the incidence of adverse events with anti-TNF used for in-
duction (RR, 0.99; 95% CI, 0.90–1.08) or maintenance of 
remission (RR, 0.93; 95% CI, 0.84–1.03) compared with 
placebo.126
The quality of evidence was rated as high with no con-
cerns for risk of bias, inconsistency, indirectness, or 
imprecision.
Discussion. There is high-quality evidence for the ef-
ficacy of anti-TNF therapy for patients who have failed 
corticosteroids, or immunosuppressant therapies. These 
subgroups are not clearly differentiated in most trials, and 
most of the RCTs included both populations. Adalimumab 
and infliximab have demonstrated efficacy in adults in RCTs 
and in children in trials with open-label induction and 
randomized dose-ranging maintenance therapy. Results 
from studies assessing certolizumab for induction of 
remission did not demonstrate significant benefit, but 
benefit was demonstrated for maintenance of remission.126 
However, there were no controlled trials in pediatric pa-
tients, and generally maintenance therapy is continued with 
the agent used for induction, making certolizumab less 
appropriate.
In pediatric patients, anti-TNF induction therapy has 
been reported only in open-label trials.130–133 For mainte-
nance, 1 double-blind RCT132 and 2 open-label RCTs 
(REACH-1131 and a French trial133) were found. None of 
these trials was placebo-controlled, but rather compared 
different doses, different dosing intervals, or scheduled vs 
on-demand therapy. The majority of patients were receiving 
concomitant immunosuppressant therapy. The 1 double-
blind RCT (IMAgINE-1) assessed adalimumab dose-ranging 
maintenance therapy after open-label weight-adjusted in-
duction therapy, and reported a remission rate of 33.5% at 
week 26, with no significant difference between high- and 
low-dose adalimumab.132 In the open-label RCT (REACH) of 
infliximab every 8 weeks vs every 12 weeks after open-label 
induction, the clinical remission rate was 56% after 1 
year.131
Impaired growth, particularly if defined by the most 
sensitive parameter of reduced height velocity, has histori-
cally been a frequent complication of pediatric CD devel-
oping before puberty. Risk factors include prolonged 
disease before diagnosis and the inter-related factors ofchronically, uncontrolled, intestinal inflammation, under-
nutrition, and chronic corticosteroid use.6,69 Anti-TNF
therapies have been associated with improved growth in
IMAgINE-2,134,135 REACH-1,131 the French trial,133 the RISK
study,136 and a prospective cohort study.137
Anti-TNFs are generally well tolerated; however,
increased risk of infections and reactivation of tuberculosis
have been reported in adults.79,138,139 In pediatric patients,
upper respiratory tract infections and nasopharyngitis were
frequent, being reported in about 37%–43% of children in
open-label extension trials.134,140 During almost 5 years of
follow-up of 100 pediatric patients who entered the
IMAgINE-2, open-label, extension study, the incidence of
opportunistic infections was 5.7% (2.2/100 patient-years),
with all but 1 being considered non-serious adverse
events.134 Only one opportunistic infection was reported in
the open-label extension of the REACH trial (n ¼ 60, up to 3-
year follow-up), also considered non-serious.140 In adults,
the risks of lymphoma were highest in those exposed to
combination therapy, but were also elevated in patients
exposed to anti-TNF monotherapy compared to no exposure
(adjusted HR, 2.41; 95% CI, 1.60‒3.64; P< .001).79
Based on the efficacy demonstrated in RCTs in adults
and children, the consensus group strongly recommended
anti-TNF therapy for patients with moderate to severe CD
who have failed corticosteroid or immunosuppressant
therapy.
Only 2 members of the consensus group reported no
conflict of interest regarding anti-TNF therapies. Two
separate votes were conducted for statement 17, one for
these 2 members, and another for the consensus group as a
whole, in both cases the vote was unanimously “strongly
agree.”
Statement 19: In patients with severe inflammatory
Crohn’s disease judged at risk for progressive,
disabling disease, we suggest anti-TNF therapy as
first-line therapy to induce and maintain clinical
remission.
GRADE: Conditional recommendation, very low-quality
evidence.
Vote: strongly agree, 47%; agree, 53%.
Key evidence. The efficacy of anti-TNF therapy in
adults with CD is described under Statements 17 and 18.
The majority of RCTs were conducted in patients who had
received previous non-biologic therapies. These data were
extrapolated to the use of these agents as first-line treat-
ments, and therefore downgraded in assessment of quality
to very-low-quality evidence.
Additional support for the early use of anti-TNF therapy
comes from open-label, prospective trials using combined
anti-TNF and immunosuppressive therapy in newly diag-
nosed, treatment naïve patients.119,141 In these studies, “top-
down” treatment was associated with significantly higher
rates of symptomatic remission at earlier time points
compared to not using early anti-TNF therapy. Post-hoc
analyses of several other adult RCTs have suggested that
rates of deep remission (clinical remission plus mucosal
Statement 20: When starting infliximab in males, we
suggest against using it in combination with a
thiopurine.
GRADE: Conditional recommendation, low-quality
evidence.
Vote: strongly agree, 40%; agree, 47%; neutral, 13%.
No consensus J: When starting infliximab in females, the
consensus group does not make a recommendation (for
or against) regarding combining it with a thiopurine to
maintain a durable clinical remission.
Key evidence. Evidence of a treatment benefit for
infliximab in combination with a thiopurine comes from the
prospective randomized SONIC trial in adults, which
demonstrated higher rates of clinical remission and endo-
scopic healing at week 26 with combination vs infliximab
monotherapy (57% vs 44%; P ¼ .02).118 In an SR&MA, this
yielded an RR of failure to achieve remission with combi-
nation vs infliximab monotherapy of 0.78 (95% CI, 0.62–
0.97).144
An SR&MA of cohort data from RCTs of anti-TNF therapy
(adalimumab, certolizumab, or infliximab), found no signif-
icant differences in the rates of clinical remission with the
healing) may be highest in patients with early CD (<18–24 
months duration) with anti–TNF-containing regimens.142,143
Discussion. Some evidence has demonstrated the 
benefits of using early anti-TNF therapy in adults who are 
treatment naïve119,141 and those who are naïve to anti-TNF 
and immunosuppressant therapy.119,142
Secondary analysis of data from the RISK observational 
study using propensity scores compared the early intro-
duction of anti-TNF therapy, immunosuppressant therapy, 
and no immunotherapy, within 3 months of diagnosis in 
pediatric patients in a real-world clinical setting.136 Early 
anti-TNF therapy was superior to early treatment with an 
immunosuppressant (85.3% vs 60.3%; RR, 1.41; 95% CI, 
1.14–1.75; P ¼ .0017), or no early immunotherapy (54.4%; 
RR, 1.57; 95% CI, 1.23–1.99; P ¼ .0002) in achieving 
corticosteroid-free remission at 1 year after diagnosis. In 
addition, the mean height z-scores increased compared with 
baseline only in the early anti-TNF group.
The consensus group suggested the use of anti-TNF 
agents as a first-line treatment based on the demonstrated 
efficacy as induction therapy, and supportive data suggest-
ing benefits in newly diagnosed patients. This was a con-
ditional suggestion because of the same concerns discussed 
under Statements 17 and 18.
The group discussed that early anti-TNF may be war-
ranted in pediatric patients with extensive disease or deep 
colonic ulcerations, or in those in whom corticosteroids 
could be expected to provide no benefit or could have the 
potential to exacerbate underlying conditions, such as 
complex perianal disease, severe bone disease, mental 
health disorders, or linear growth delay. The group also 
emphasized that there is an urgent need for better pre-
dictors of chronically active, severe inflammatory disease, 
and disease that will result in progressive intestinal damage 
that would necessitate intestinal resection.combination of an anti-TNF plus an immunosuppressant
(thiopurine or methotrexate) compared to an anti-TNF
alone for induction (OR, 1.28; 95% CI, 0.77–2.16) or main-
tenance therapy (OR, 1.02; 95% CI, 0.80–1.31).145 There
were no significant differences in rates of clinical remission
between monotherapy and combination therapy for main-
tenance treatment when the 3 anti-TNF agents were pooled,
or when they were analyzed separately.
In the SONIC trial, the incidence of adverse events was
generally similar in the combination and monotherapy
groups, and there were no significant differences in the RR
of serious infection.118,144 Evidence on rare, but important
adverse events was very low quality. Observational data
suggest a higher risk of lymphoma79 and activation of
tuberculosis138 in patients exposed to combination vs anti-
TNF monotherapy.
One open-label, pediatric RCT randomized patients after
10 weeks of combination induction therapy to maintenance
with either 54 weeks of combination therapy or 26 weeks of
combination therapy, followed by 26 weeks of anti-TNF
monotherapy.146 At the end of the 10-week open induc-
tion phase, 65.5% of patients were in clinical remission. At
the end of the 54-week maintenance phase, there was no
significant benefit of combination therapy with <5% of
patients in either group experiencing a loss of response. The
incidence of serious adverse events was 9%, of which the
most common was primary Epstein-Barr virus infection.
The evidence was downgraded to low due to serious
inconsistency and serious imprecision.
Discussion. In the REACH pediatric study of infliximab,
all patients were required to be administered immunosup-
pressants, and 10-week remission rates were 59%. How-
ever, there was no monotherapy comparison group.131 One
RCT in adults (downgraded to low-quality evidence for
indirectness [extrapolated to pediatric] and imprecision
[low number of events]) suggested a potential efficacy
benefit with combination therapy over anti-TNF mono-
therapy. However, administration of infliximab mono-
therapy in the SONIC study was strictly according to
standard protocol (precisely 5 mg/kg every 8 weeks)
without any attention to optimizing drug exposure via
therapeutic drug monitoring. There is also an important
benefit of concomitant immunomodulators in prolonging
clearance of infliximab and reducing rates of anti-infliximab
antibody development, as demonstrated in SONIC and in
pediatric cohort studies.137,147 Avoiding secondary loss of
response related to anti-drug antibody development is
extremely important in young patients, given the long lives
ahead, during which treatment will be needed. The modest
increment in efficacy of combination therapy might be
overcome via individualized dosing regimens of infliximab
monotherapy to avoid low or absent trough titers to help
avoid development of anti-drug antibodies.
The consensus group recognized the improved durability
of infliximab response with combination therapy, but sug-
gested against selection of thiopurines as the concomitant
drug for males based on safety concerns, as described in
Statements 12 and 13. Specifically, the risk of the extremely
rare but almost uniformly fatal HSTCL, is attributable to
Statement 21: When starting adalimumab in males, we
suggest against using it in combination with a
thiopurine.
GRADE: Conditional recommendation, very-low-quality
evidence.
Vote: strongly agree, 40%; agree, 53%; neutral, 7%.
No consensus K: When starting adalimumab in females,
the consensus group does not make a recommendation
(for or against) regarding combining it with a thiopurine
to maintain a durable clinical remission.
Key evidence. An open-label, RCT (DIAMOND), in
adults who were immunosuppressant- and biologic-naïve
found no difference in 26-week clinical remission rates be-
tween the combination of adalimumab plus azathioprine
(68.1%) and adalimumab monotherapy (71.8%; P ¼ .63).
The rate of endoscopic improvement was significantly
higher with combination therapy at 6 months but not 12
months.149 Similarly, post-hoc analyses of cohort data from
RCTs in adults did not show a significant benefit with
combination adalimumab and immunosuppressant therapy
(thiopurine or methotrexate) over adalimumab alone for
induction (OR, 0.88; 95% CI, 0.60–1.27) or maintenance of
remission (OR, 0.88; 95% CI, 0.58–1.35).145
Additional very low quality of evidence data in pediatric
patients also reported no benefit with the combination of ada-
limumab plus an immunosuppressant. In a post-hoc analysis of
the IMAgINE-1 RCT, there was no difference in remission rates
between those who received concomitant immunosuppres-
sants and those who did not (35.9% vs 29.6%).132,150
thiopurine use, both alone and in combination with anti-TNF. 
The highest risk has been reported among males aged <35 
years receiving combination thiopurine and anti-TNF ther-
apy.148 Post-marketing surveillance of infliximab continues 
to identify at least 2 occurrences worldwide annually and 
always in patients receiving anti-TNF in combination with a 
thiopurine. Two such occurrences were reported in the 
DEVELOP pediatric IBD registry.91
In adults, the risk of other lymphomas (usually Epstein-
Barr virus–driven), which is age-related and of lesser 
concern for pediatric patients, was increased in patients 
exposed to combination thiopurine plus anti-TNF therapy 
compared to no exposure, thiopurine monotherapy, or anti-
TNF monotherapy.79 In the open-label, RCT in 84 pediatric 
patients, there were 4 occurrences of primary EBV infection, 
1 of herpes simplex virus, and 1 of chickenpox infection, 
throughout the study.146
The group concluded that the benefits of thiopurine in 
combination with infliximab did not outweigh the risk of 
HSTCL in males. However, the consensus group did not 
make a recommendation regarding the use of combination 
therapy for females. The risk of HSTCL, although lower in 
females, remains elevated compared to no exposure, 
therefore, some participants argued that the risks out-
weighed the benefits, while others disagreed and noted that 
combination therapy with thiopurines remains a potentially 
useful strategy for some patients.The evidence was downgraded to very low due to
serious risk of bias and very serious imprecision.
Discussion. There were very few data to suggest a
benefit of adding a thiopurine when starting adalimumab
therapy. In the DIAMOND trial, the primary end point was
negative, but there was evidence of more rapid mucosal
healing in the combination group.149
Although not statistically significant, there were trends
toward higher adalimumab trough levels and lower rates of
anti-adalimumab antibodies in the combination group
compared to the monotherapy group. Although overall there
were not significant differences in the rates of adverse
events or study discontinuations between the combination
and monotherapy groups, withdrawals specifically for side
effects were significantly more frequent in the combination
group.
For the same reasons as described in Statement 20 for
infliximab/thiopurine combination therapy regarding safety
concerns and less evidence of benefit, the consensus group
suggested against the combination in males and did not
make a recommendation regarding the use of combination
therapy in females.
Statement 22: In male patients with Crohn’s disease
receiving immunomodulator therapy in combination
with an anti-TNF therapy, we suggest methotrexate
in preference to thiopurines.
GRADE: Conditional recommendation, very-low-quality
evidence.
Vote: strongly agree, 27%; agree, 53%; neutral, 20%.
Key evidence. SRs have found few studies assessing
the efficacy of concomitant methotrexate.129,145 One RCT,
the COMMIT study, compared the efficacy of combination
therapy with infliximab plus methotrexate to infliximab
alone, and found no difference in rates of symptomatic
remission between the 2 treatment groups (HR, 1.16; 95%
CI, 0.62–2.17; P ¼ .63).151 A very, small, open, pilot study
reported an early benefit of combination therapy that was
not sustained.152
The open-label, RCT in pediatric patients, described
under Statement 20, included patients on either azathio-
prine or methotrexate in the combination treatment group,
but did not specify the proportion receiving each drug.
Overall combination therapy with infliximab plus an
immunosuppressant was not associated with a benefit over
infliximab alone in preventing loss of response over the 1-
year follow-up.146 Similarly, in the RCT assessing adalimu-
mab in pediatric patients (IMAgINE-1), >60% of patients
received immunosuppressants; however, the proportion
receiving methotrexate was not reported, and a post-hoc
analysis did not demonstrate a difference in remission
rates between those who received concomitant immuno-
suppressants and those who did not.132,150 All pediatric
patients in the REACH study received concomitant immu-
nosuppressants, but only 10% specifically received
methotrexate.131
The quality of evidence was downgraded to very low due
to serious risk of bias and very serious imprecision.
Statement 23: In patients with Crohn’s disease who
have a suboptimal clinical response to anti-TNF
induction therapy or loss of response to maintenance
therapy, we suggest regimen intensification informed
by therapeutic drug monitoring.
GRADE: Conditional recommendation, very-low-quality
evidence.
Vote: strongly agree, 53%; agree, 47%.
Key evidence. One RCT (TAXIT) evaluated the efficacy
of regular therapeutic drug monitoring (TDM) in adults
with IBD, who were stable on infliximab maintenance
therapy, and had their dose proactively optimized before
study entry to achieve an infliximab trough concentration
between 3–7 mg/mL.154 Among CD patients, there was no
significant difference in clinical remission rates between
those who were randomized to dosing guided by TDM and
those randomized to standard clinically-based dosing
(62.6% vs 54.9%; P ¼ .353). Relapse rates were signifi-
cantly lower in patients who received TDM-based dosing
Discussion. Although the double-blind, placebo-
controlled RCT failed to show a benefit with combination 
anti-TNF and methotrexate therapy, the evidence was 
assessed as very low quality.151 The trial demonstrated 
that combination infliximab plus methotrexate was asso-
ciated with a lower likelihood of developing antibodies to 
infliximab (4% vs 20%; P ¼ .01), and  there was a trend  to
higher median serum trough infliximab concentrations 
(6.35 mg/mL vs 3.75 mg/mL; P ¼ .08). However, there was 
no significant clinical benefit. Of note, there were very high 
success rates among the patients in this trial, potentially 
due to the use of systemic corticosteroids to induce 
remission in all patients. The high success rate in both 
arms of the trial may have resulted in a lack of power to 
demonstrate clinical benefit of concomitant
methotrexate.151
The most frequent adverse event with methotrexate 
therapy is nausea (up to 25% of patients), however, there is 
a risk of rare, but serious adverse events, including hepa-
totoxicity, bone marrow suppression, hypersensitivity 
pneumonitis, gastrointestinal toxicity, teratogenicity, and 
infections.153 In contrast to thiopurines (see Statement 20), 
methotrexate has not been associated with an increased 
incidence of lymphoma, however, historic rates of use in CD 
are low.153
Although a vote was conducted, both insufficient evi-
dence and lack of consensus prevented the group from 
making a recommendation regarding combining infliximab 
or adalimumab with methotrexate to maintain a durable 
clinical remission in all patients or males alone. However, if 
a clinician judges a patient to require the combination of an 
anti-TNF and an immunosuppressant, the consensus group 
suggested that methotrexate should be used over thio-
purines in males. This was a conditional suggestion, as, 
despite the lower risk of lymphoma, there are other safety 
concerns in addition to a lack of evidence demonstrating 
the efficacy of combination therapy with methotrexate 
in CD.compared to those who received clinically based dosing
(17% vs 7%; P ¼ .018); however, this was in the combined
IBD population.
The majority of data related to TDM come from obser-
vational studies, which have been assessed in SR&MAs of
studies in adults using infliximab155,156 or adalimumab.157
These analyses showed that antibodies to anti-TNFs were
associated with greater likelihood of loss of response,156,157
and higher serum anti-TNF levels were associated with a
greater probability of clinical remission and mucosal heal-
ing.155,157 However, these studies do not assess whether
using TDM proactively will have an impact on patient out-
comes, as opposed to reactive TDM when patients are
symptomatic.
In the IMAgINE-1 study in pediatric patients, higher
trough levels were associated with greater rates of remis-
sion, but there was no correlation between antibodies to
anti-TNF therapy and remission/response (n ¼ 6 patients
with antibodies).158 In a retrospective case series of pedi-
atric patients with IBD, those with very low infliximab drug
levels had high rates of infliximab antibodies, non-response,
or loss of response.159
The quality of evidence was downgraded to very low due
to serious risk of bias and very serious imprecision.
Discussion. Evidence suggests that regimen intensi-
fication (increasing the dose or shortening the dosing in-
terval) may help increase remission rates. In TAXIT, dose
optimization before randomization resulted in significant
improvements in remission rates (88% vs 65%; P ¼ .02)
and median C-reactive protein concentrations (3.2 mg/L
vs 4.3 mg/L; P < .001) compared to before dose escala-
tion.154 Two SRs of case series have shown response rates
of about 54%–90%, and remission rates of about 31%–
40% among patients who underwent dose intensifica-
tion.160,161 In addition, among pediatric patients losing
response in the REACH trial, planned dose intensification
resulted in 75% of patients (n ¼ 24/32) regaining
response.131
Observational data suggest that antibodies to anti-TNFs
are associated with greater likelihood of loss of response,
and higher serum anti-TNF levels are associated with a
greater likelihood of maintained remission. However, the
only RCT that prospectively assessed the impact of proac-
tive TDM to guide dosing during infliximab maintenance
therapy demonstrated no significant benefit in its primary
outcome of higher clinical remission rate at 1 year.154 In a
small, single-blind RCT, treatment of secondary anti-TNF
failure using an algorithm based on combined drug serum
levels and antibody measurements significantly reduced
average treatment costs per patient compared with routine
dose escalation.162 The TDM-guided approach did not have
a negative effect on clinical efficacy, and was cost-effective
during longer-term follow-up.163
Based on the evidence that regimen intensification can
improve outcomes, the consensus group suggested this
strategy before considering a change in therapy. The state-
ment was a conditional suggestion because of uncertainties




No consensus L: In patients with Crohn’s disease who
have achieved a clinical remission with anti-TNF
therapy, the consensus group does not make a
recommendation (for or against) regarding assessment
for mucosal healing within the first year to determine the
need to modify therapy.
Key evidence. Evidence for the potential benefits of
mucosal healing and the rates of mucosal healing with anti-
TNF therapy were discussed under Statement 16.
Discussion. The discussion around the utility of assess-
ing for mucosal healing was discussed under Statement 16.
In the context of anti-TNF therapy, the consensus group
did not make a recommendation regarding endoscopic
assessment of mucosal healing among patients in clinical
remission. Data concerning endoscopic healing achieved
with other agents, including alternate pathway biologic
therapies, are very sparse. In addition, the degree of
mucosal healing warranting a change in therapy has not
been defined, nor has the ideal duration of therapy before
assessing for endoscopic healing.
Non-Anti–Tumor Necrosis Factor Biologic
Therapy
Statement 24: In patients with moderate to severe
Crohn’s disease who fail to achieve or maintain
clinical remission with anti–TNF-based therapy, we
suggest ustekinumab to induce and maintain clinical
remission.
GRADE: Conditional recommendation, moderate-quality
evidence for induction, moderate-quality evidence for
maintenance.
Vote: strongly agree, 47%; agree, 53%
Key evidence. Evidence for the efficacy of ustekinu-
mab for induction of remission was available from 4 RCTs in
adult patients, including both patients who had and those
who had not failed anti-TNF therapy.164–166 In an SR&MA of
these 4 trials (n ¼ 1947), ustekinumab was significantly
better than placebo for the outcome of failure to achieve
remission (RR, 0.91; 95% CI, 0.86‒0.95).167
Two RCTs were conducted in patients who had previ-
ously failed anti-TNF therapy.164,165 In CERTIFI, there were
no significant differences in remission rates at week 6,
despite ustekinumab being associated with a higher
response rate compared to placebo.165 However, in the
UNITI-1 trial, 1 intravenous infusion of ustekinumab at 6
mg/kg resulted in improved rates of both response (34%)
and remission (21%) at week 8, compared to placebo (22%
and 7%, respectively).164
Two RCTs assessed the use of ustekinumab as mainte-
nance therapy in patients who previously failed anti-TNF
therapy.164,165 In the CERTIFI trial, ustekinumab resulted
in significantly increased rates of clinical remission at 22
weeks compared with placebo (41.7% vs 27.4%; P ¼
.03).165 In the combined population in the UNITI-IM trial,
which included responding patients who had previouslyfailed either anti-TNF or were biologic-naïve but had failed
conventional therapy, significantly more patients were in
remission with maintenance ustekinumab after 1 year of
treatment compared to placebo (49%–53% vs 36%). In the
UNITI-1 subgroup of patients with prior anti-TNF failure,
there were no significant differences in clinical remission
rates between ustekinumab and placebo at 1 year.164
In the SR&MA, there were no significant differences in
the rates of adverse events, serious adverse events, or
withdrawals due to adverse events.167
No RCTs assessing ustekinumab in pediatric patients
with CD were found.
The quality of evidence was downgraded to moderate
due to indirectness with respect to populations (lack of
pediatric data).
Discussion. Ustekinumab has demonstrated efficacy
for induction and maintenance of remission in the overall
patient population, as well as patients who have previously
failed or were unable to tolerate anti-TNF therapy.
No RCTs in pediatric patients with CD were found;
specific, pediatric case-series and experience among par-
ticipants are still limited.168–170 Among the 6 cases reported,
all had previous primary or secondary failure, or intolerance
to, anti-TNF therapy, and 3 of the 6 successfully achieved
clinical remission.
Ustekinumab has been studied in a RCT in adolescent
patients from 12 to 17 years of age with plaque psoriasis.171
There were no significant differences in the rates of adverse
events between ustekinumab and placebo at 12 weeks.171
Infections were the most common adverse events, primarily
nasopharyngitis, upper respiratory tract infections, and
pharyngitis. During the 60-week follow-up, there were no
reportedmalignancies, tuberculosis, opportunistic infections,
anaphylactic reactions, or serum sickness-like reactions.
Based on the evidence for efficacy in adults and the re-
ported safety in pediatric patients with plaque psoriasis, the
consensus group made a conditional suggestion in favor of
ustekinumab therapy in patients who have failed anti-TNF
therapy. This was a conditional suggestion because of the
lack of RCTs in pediatric patients with CD and the modest
effect sizes in the adult trials.
No consensus M: In patients with moderate to severe
Crohn’s disease who fail to achieve or maintain clinical
remission with an anti-TNF–based therapy, the
consensus group does not make a recommendation (for
or against) regarding the use vedolizumab to induce and
maintain clinical remission.
Key evidence. Evidence for the efficacy of vedolizu-
mab for induction therapy was available from 3 RCTs in
adults with CD who had previously failed anti-TNF ther-
apy.172,173 or had no prior anti-TNF exposure,174 which have
been analyzed in several SR&MAs.129,175 For the outcome of
failure to induce symptomatic remission, vedolizumab was
superior to placebo in the combined patient group (RR,
0.87; 95% CI, 0.79‒0.95), and trended to benefit in the
subgroup of patients who had previously failed anti-TNF
therapy (RR, 0.89; 95% CI, 0.78–1.01).175
 
In the RCT that assessed the efficacy of vedolizumab 
maintenance therapy among responders to induction ther-
apy, vedolizumab resulted in significantly higher 1-year 
remission rates compared to placebo (36%‒39% vs 22%; 
OR, 2.20; 95% CI, 1.40–3.44).129,172 Among those who had 
previously failed anti-TNF therapy, but who achieved clin-
ical “response” at week 6 and were then re-randomized to 
vedolizumab vs placebo maintenance therapy, continuation 
of vedolizumab was significantly more effective than pla-
cebo.172 There were no significant differences in the rates of 
serious adverse events, infections, or malignant neoplasms 
between vedolizumab and placebo.129
The evidence was assessed as very low quality due to 
the significant heterogeneity among the induction studies, 
as well as imprecision and indirectness. No RCTs assessing 
vedolizumab in pediatric patients with CD were found.
The evidence was downgraded to very low due to 
serious inconsistency, indirectness with respect to pop-
ulations (paucity of pediatric data), and serious imprecision.
Discussion. No RCTs in pediatric patients with CD 
were found, but a small, prospective observational study176 
and case reports177,178 suggest it may be beneficial in some 
children who have previously failed anti-TNF therapy. In the 
prospective study, 25% of patients with CD achieved 
remission at week 14 and 31% at week 22.176 The retro-
spective case reports of pediatric patients with IBD found 
that vedolizumab tended to be slower acting and have lower 
remission rates in patients with CD compared to those with 
ulcerative colitis.177,178 Long-term, open-label follow-up 
data report low rates of infusion reactions, serious in-
fections, and malignancy.179,180
The consensus group did not make a recommendation 
for or against the use of vedolizumab in patients who had 
failed prior anti-TNF therapy. Vedolizumab did not show a 
significant benefit over placebo for induction of remission in 
prior treatment failures in the SR&MA.175 One RCT in the 
setting of maintenance of remission suggested benefit in
patients who had responded to vedolizumab induction 
therapy compared to placebo, but anticipated efficacy is 
overall very low in this anti-TNF failure population.172 
Finally, there were no RCTs in pediatric patients in any 
disease state, and very limited safety data in the pediatric 
population. It is anticipated that experience will gradually 
accrue in pediatric patients with less treatment-refractory 
disease. In the current era of access only for patients hav-
ing failed anti-TNF, the consensus group concluded that 
evidence of efficacy in CD was less convincing than that for 
ustekinumab, the other non-anti-TNF biologic.Statement 25: In patients with Crohn’s disease, we
recommend against cannabis or derivatives to induce
or maintain remission.
GRADE: Strong recommendation, very-low-quality
evidence.
Vote: strongly agree, 87%; agree, 7%; neutral, 7%.
Alternative TherapiesKey evidence. Cannabis or derivatives has been
assessed in 2 small RCTs in adults with CD inadequately
controlled on steroids, immunomodulators, or anti-TNF
therapy.181,182 Both trials reported no significant differ-
ences in remission rates with either medical cannabis cig-
arettes or oral cannabidiol compared to placebo.181,182
These studies included a total of 40 patients. No side ef-
fects and no withdrawal symptoms on discontinuation were
reported. A patient survey reported higher rates of surgical
intervention among patients with IBD who smoked cannabis
to relieve their symptoms, compared to those who did
not.183 However, because of the cross-sectional design, this
could represent reverse causation.
The quality of evidence was downgraded to very low due
to serious risk of bias, serious indirectness with respect to
populations (no pediatric data), and very serious
imprecision.
Discussion. There is increasing interest in medical
marijuana; however, there is currently no support for the
use of cannabis for the treatment of CD. Although one RCT
showed improvement in quality of life with cannabis ciga-
rettes,181 both RCTs demonstrated no significant benefit of
cannabis for clinical remission, or an objective measure of
disease activity (C-reactive protein).181,182
A review of the literature by the Canadian Paediatric
Society concluded that cannabis use during adolescence can
cause changes to the developing brain, and has been linked
to substance use disorders, tobacco smoking, increased
rates of psychiatric illnesses, cognitive decline, and dimin-
ished school performance and lifetime achievement.184,185
They recommended that sales of all cannabis products to
children and adolescents be prohibited in order to protect
these individuals from the potential harms associated with
cannabis use.184,185
Based on the lack of evidence for efficacy in the treat-
ment of CD, and the potential harms associated with
long-term use, the consensus group made a strong recom-
mendation against the use of cannabis products in pediatric
patients with CD.Future Research Directions
The management of CD in pediatric patients has been
inadequately studied, with most data being extrapolated
from studies in adult patients. Overall, there is a need for
more RCTs of CD management strategies in pediatric pop-
ulations, including positioning of biologic therapies relative
to immunomodulators. The identification of molecular
markers predictive of disease course would constitute a
significant advance, allowing early selection of the most
appropriate treatment plan for individual patients. More
data are needed to define the efficacy and optimal protocol
for EEN in pediatric patients, especially as a first-line
treatment.
There is an absence of RCT data on the use of non–anti-
TNF biologic therapies in pediatric patients, for both in-
duction and maintenance therapy. The role of switching out
of class in pediatric patients who have achieved clinical
remission with anti-TNF therapy should be assessed. All 
trials in pediatric CD should include outcomes of mucosal 
healing and, importantly, should strive to determine the 
degree of healing required to meaningfully modify the long-
term course of the disease beginning in childhood.Summary
Previous guidelines on the medical management of pe-
diatric Crohn’s disease were developed through traditional 
expert consensus-based methodology without formal 
assessment of the quality of evidence.8 The current guide-
lines present recommendations for pediatric patients with 
CD based on the GRADE framework with systematic review 
of the literature and rigorous assessment of the quality of 
evidence. Consensus was reached for or against 25 state-
ments relating to main treatment options: aminosalicylates, 
budesonide, systemic corticosteroids, exclusive enteral 
nutrition, thiopurines, methotrexate, anti-TNF biologics, 
non–anti-TNF biologics, and cannabis (Table 1). When 
consensus was not reached for a particular statement even 
after a thorough systematic review of the quality of evi-
dence, balance of harms and benefits, values and prefer-
ences, as well as resource use, no recommendation was 
made. Instead, we presented the evidence and discussed the 
reasons we were not able to make a judgment. It is hoped 
that the available information will enhance the discussion 
between the clinician and the patient and enable the patient 
to make an evidence-based informed decision that is 
consistent with his or her own values and preferences.
It is important to note that there is discordance in the 
strength of recommendation and quality of evidence in 7 
statements where strong recommendations were made 
against certain treatments based on low- or very-low-
quality evidence of no benefit, but of potential harms due 
to side effects of medications. A judgment was made by the 
consensus group that there was also harm in not providing 
more effective treatment options in children. The implica-
tions of inadequately treated CD are of particular impor-
tance in children because of the potentially serious and 
irreversible consequences of growth impairment, delayed 
sexual maturation, as well as psychosocial, mental, and 
emotional maldevelopment. These effects may be long-
lasting, persisting even after recovery from the disease. 
Undoubtedly, there is subjectivity in making this judgment 
regarding the strong desirability of avoiding irreparable 
harms to a child. However, GRADE does not seek to elimi-
nate subjective judgments (appropriate or inappropriate). 
Such judgments are an inevitable part of rating evidence and 
making recommendations, but one merit of the GRADE 
system is that judgments are made in a systematic, explicit, 
and transparent manner.
While the goal of therapy is typically deep remission 
(clinical remission and mucosal healing), this could not be 
selected as the primary outcome for this guideline because, 
until recently, only clinical remission and response (not 
mucosal healing) have been assessed in the majority of 
RCTs. However, the consensus group endorsed the impor-
tance of achieving endoscopic mucosal healing, whileacknowledging that more research is required to fully un-
derstand other aspects of intestinal healing, including the
transmural nature of the disease and submucosal inflam-
matory histology.
These guidelines should help to optimize the use and
proper positioning of existing medical therapies and
improve outcomes in pediatric patients with CD. However,
substantial unanswered questions remain. Studies in pedi-
atric patients are needed to define optimal use of exclusive
EN, positioning of biologic therapies vs immunomodulators,
and of established anti-TNF agents vs emerging alternate
pathway biologic therapies. As well, with the rapid advent of
new treatments and therapies for CD, the term conventional
therapy may become obsolete, as many of today’s novel
therapies will become tomorrow’s standard treatments.
These guidelines will be reconsidered and updated as
appropriate when important new evidence emerges.Canadian Association of
Gastroenterology Statement
This clinical practice guideline (CPG) on the manage-
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providing optimal care to patients and families, and can be
subject to change as scientific knowledge and technology
advance and as practice patterns evolve. The CPG is not
intended to be a substitute for physicians using their indi-
vidual judgment in managing clinical care in consultation
with the patient, with appropriate regard to all the indi-
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